REGISTRATION INFORMATION - SNO · This year’s gala dinner, the social highlight of the meeting,...

P R E L I M I N A R Y P R O G R A M and

R E G I S T R AT I O N I N F O R M AT I O N

22 N D A N N UA L M E E T I N Gand E D U C AT I O N D AY

O F T H E S O C I E T Y F O R N E U R O - O N C O L O G Y

November 16-19, 2017Marriott Marquis

San Francisco, California

MEETING OVERVIEW

The 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology will take place at the Marriott Marquis Hotel in San Francisco, California. With a prime location in central San Francisco, only blocks away are museums, shops, restaurants, cable cars, Chinatown, Union Square and many other popular attractions. The Marriott Marquis offers panoramic views of the city from its 39th floor sky high bar and is only 13 miles from the San Francisco International Airport and 19 miles from Oakland International airport. In addition to a lively downtown, there are many sites to explore with unique neighborhoods in hilly terrain, waterfront districts, trendy bistros and beautiful views of the Golden Gate Bridge.

This year’s Education Day will focus on two of the Cancer Moonshot Blue Ribbon Panel recommendations, “Developing Ways to Overcome Cancer Resistance,” and “Minimizing Cancer Treatments Debilitating Side Effects.” In addition to concurrent sessions with both Basic Science and Applied Neuro-Oncology presenting a comprehensive view of these topics, there will also be morning and afternoon joint sessions with exciting talks from prominent keynote speakers and lively discussion panels.

This year’s Scientific Meeting will highlight a number of the 10 Blue Ribbon Panel recommendations related to the Cancer Moonshot program. Dr. W. K. Alfred Yung, a member of the Blue Ribbon Panel, will present an introduction to the Moonshot program. Additional keynote presentations from Dr. Jennifer Doudna, Dr. Walter Koroshetz, Dr. Ludmil Alexandrov and Dr. Carlo Croce will provide further insights into specific approaches in meeting the goals of these Cancer Moonshot recommendations. These and additional key talks and sessions related to the Moonshot initiative are identified by the Moonshot logo.

EDUCATIONAL OBJECTIVES

After attending this conference, participants should be able to: • Discuss new CNS cancer technologies in the areas of cell biology, cell

signaling, genetics, epigenetics, immunology, stem cells, metabolomics, tumor microenvironment, angiogenesis and radiobiology (knowledge);

• Identify ways to overcome cancer resistance (knowledge);• Apply information on minimizing side effects from cancer treatment

(knowledge, competence, performance, patient outcomes);• Describe new advances in the treatment of CNS metastases

(knowledge);• Apply advances in neuro-imaging and neuropathology to diagnose,

prognose, and measure response to therapy for patients with CNS tumors (knowledge, competence, performance, patient outcomes);

• Apply therapeutic strategies and clinical trial designs related to new molecular biology research relevant to CNS tumors (competence);

• Using neurocognitive intervention strategies, create a plan to diminish the impact of brain tumors and their treatments on patients and quality of life (knowledge, competence, performance, patient outcomes)

TARGET AUDIENCE This conference should be of value to neuro-oncologists, medical oncologists,adult and pediatric neurosurgeons, pediatric neuro-oncologists, neuroradiologists, neuropathologists, radiation oncologists, neuro-psychologists, epidemiologists, basic and translational scientists and nurses.

EDUCATIONAL METHODS

Lectures, Question-and-Answer Sessions, Panel Discussions, Posters, etc. EVALUATION

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 27.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The presentations included in the Applied Neuro-Oncology (Quality of Life) Interventions section have been designated by The University of Texas MD Anderson Cancer Center for 2.5 AMA PRA Category 1 CreditsTM in medical ethics and/or professional responsibility.

Building on the success of past SNO meetings, sunrise sessions, plenary and concurrent sessions will be featured with oral abstract presentations, enhanced oral eTalk electronic poster presentations, and poster presentations. Special lunch tutorials and industry-sponsored symposia will provide in-depth information on evolving technologies and therapeutics. Circulated for viewing throughout the meeting will be webcasts with “Meet the Expert” recordings of esteemed scientists and clinicians on topics such as mouse models, The Cancer Genome Atlas, telomeres, genetics and epigenetics of pediatric brain tumors, and immunology checkpoint inhibitors. The SNO Daily Highlights will again be recorded for viewing, with invited discussants reviewing the most cutting-edge science from that day’s basic science and clinical research presentations. Interactive ePoster touch screens will be available throughout the meeting.

Cancellations must be received in writing no later than November 8; registration fees will be refunded less a $50 handling fee. Cancellations received after November 8 cannot be refunded, but the meeting registration can be transferred to another person with written authorization. E-mail all cancellation and transfer requests to Program Registrar Linda Greer, [email protected].

SCIENTIFIC COMMITTEE

Scientific Meeting Chairs Manish AghiFrank Furnari

Vinay Puduvalli

Education Day ChairsSusan Bell

Robert CavaliereAlbert Kim Khalid Shah

CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates awarding AMA PRA Category 1 CreditsTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form. Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially influence the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

GALA DINNER

This year’s gala dinner, the social highlight of the meeting, will feature a “Take Me Out to the Ballgame” theme and will be held at the world-renowned AT&T Park on Saturday evening, November 18th. AT&T Park, with its breathtaking views and classic design, also serves as the Giants’ home. Enjoy an evening of ball park fun with live entertainment, dancing and craft beer tastings. The gala will also feature indoor batting tunnels and allow the opportunity to hit balls in the same tunnels where Hunter Pence and Buster Posey hone their swings, as well as a behind the scenes tour of AT&T Park. Be sure to dress in comfortable “ballpark” wear.

Deluxe motor coaches will transfer you on a short 15-minute ride from the host hotel to an amazing and memorable night full of fun. A gala dinner ticket can be added to your registration at any time. Tickets are limited and were sold out at last year’s meeting. We strongly suggest you purchase your tickets early as they are first-come, first serve. We hope you will join us for this very special evening!

REGISTRATION INFORMATION

Register Online: www.soc-neuro-onc.org. Online registration is the preferred method of registering for the meeting. Registrants can pay with a major credit card or, alternatively, can choose to pay by check, bank transfer, or money order. If you require a paper registration form, or have questions about registration, please contact Linda Greer, Tel. (346) 980-6935. Email: [email protected]. We prefer payment prior to arrival in San Francisco. Please note that a surcharge will be assessed for all on-site registrations and/or registration payments.

ACCOMMODATIONS

The San Francisco Marriott Marquis Hotel is the conference venue for this year’s meeting. Located just south of Market Street in SoMa, this centrally located downtown San Francisco hotel offers easy access to the city’s best attractions. The discounted room rate at the Marriott is only $215.00 per night. Additional hotel options are listed on the SNO website, and a shuttle bus will be provided to and from the Marriott. Special Assistance: Contact SNO at (346) 980-6935 if you have any special dietary or ADA accommodation needs.

REFUNDS /CANCELLATIONS

The pre-registration deadline for the lowest registration rates is September 15, 2017, 11:59pm, CST. The online registration deadline is November 8. For registrations after this date, attendees must register on-site and on-site surcharges will apply.

REGISTER FOR SPECIAL PRE-CONFERENCE SESSIONS STARTING NOVEMBER 15!

Attendees have the option of registering for the following special pre-conference sessions:

NEURO-ONCOLOGY REVIEW COURSEChair: Maciej Mrugala

SNO is pleased to announce a full-day Neuro-Oncology Review Course as part of its educational programs for 2017. The course

will take place on Wednesday, November 15.

SNO-SCIDOT CONFERENCE ON THERAPEUTIC DELIVERY TO THE CNS

Co-Chairs: Manish Aghi (SNO), Michael Vogelbaum (SCIDOT) Following the success of the first meeting in 2015, SNO is pleased

to host the second SNO-SCIDOT Conference on Therapeutic Delivery to the CNS, which will be held Wednesday/Thursday,

November 15-16, immediately prior to the SNO Annual Meeting.

PROGRAM DETAILS ARE INCLUDED FURTHER IN THIS BROCHURE. TO REGISTER FOR EITHER OF THESE

PRE-CONFERENCE SESSIONS, VISIT THE SNO WEBSITEwww.soc-neuro-onc.org

NEW THIS YEAR! The SNO meeting will provide some exciting new

features this year including:

• CLAIM CME CREDIT DIRECTLY THROUGH THE APP

• ENHANCED “TEXT TO MODERATOR” ELECTRONIC Q&A

• INTEGRATED ORAL ETALKS AND TRADITIONAL POSTER PRESENTATIONS

• SELECTED SESSIONS SIMULCASTED ON HOTEL IN-ROOM TV

• EXPANDED E-POSTERS WITH 45 FLAT SCREENS PLACED THROUGHOUT THE MEETING SPACE

• NEW PRESENTATION MANAGEMENT SYSTEM FOR EASIER UPLOAD OF ORAL PRESENTATIONS

• CAPTURE OF SELECTED CONTENT FOR POST-MEETING EDUCATION SITE

Chair: Maciej Mrugala

P R E - C O N F E R E N C E S E S S I O N SWednesday, November 15, 2017 I Neuro-Oncology Review Course

Back for a 4th consecutive year, the Neuro-Oncology Review Course will be held Wednesday, November 15. This fast paced, full-day activity will provide high quality education and CME credits for all participants. Practicing physicians, residents and fellows, medical students, nurse practitioners, nurses, and all those interested in reviewing and enhancing their knowledge in the principles of clinical neuro-oncology will benefit from this program. The faculty of the course, selected from top neuro-oncology programs, will offer a comprehensive overview of clinical neuro-oncology.

6:00-7:15am Registration

6:00-7:15am LIGHT CONTINENTAL BREAKFAST Foyer

7:15-7:20am Welcome and Introduction Maciej Mrugala

7:20- 8:00am Neuro-radiology pearls for the neuro-oncologist James Fink

8:00-8:45am Primary brain tumors- pathology, grading and prognosis- new WHO classification Peter Canoll

8:45-9:25am Neurosurgical management of brain tumors Michael Lim

9:25-10:05am Medical complications in neuro-oncology patients Katherine Peters

10:05-10:25am BREAK

10:25-1:10am Management of primary CNS tumors- PART 1- gliomas Erin Dunbar

11:10-11:50am Principles of radiotherapy in neuro-oncology and its side effects Helen Shih

11:50-12:55pm LUNCH

12:55-1:35pm Metastatic disease in the nervous system – brain/spine metastases Manmeet Ahluwalia

1:35-2:20pm Management of primary brain tumors- PART II- non-glial tumors Rimas Lukas

2:20-3:00pm Chemotherapy in neuro-oncology: principles and practice David Peereboom

3:00-3:45pm Pediatric neuro-oncology highlights Sonia Partap

3:45-4:05pm BREAK

4:05-4:45pm Non-metastatic neurologic complications of cancer Lisa Rogers

4:45-5:25pm Palliative care for a neuro-oncologist Lynne Taylor

5:25-6:00pm Metastatic disease in the nervous system – neoplastic meningitis Maciej Mrugala

6:00pm ADJOURN

P R E - C O N F E R E N C E S E S S I O N S Wednesday, November 15, 2017 I Therapeutic Delivery to the CNS

The 2017 SNO-SCIDOT Conference on Therapeutic Delivery to the CNS will be held on November 15 - 16th, immediately preceding the SNO Annual Meeting. This conference is jointly hosted by the Society for Neuro-Oncology (SNO) and the Society for CNS Interstitial Delivery of Therapeutics (SCIDOT) and will address the multiple laboratory and clinical advances that have been made in the field of interstitial delivery of therapeutics.

Co-Chairs: Manish Aghi (SNO), Michael Vogelbaum (SCIDOT)

6:00-8:00am Registration


8:00-8:10am Welcome and Introduction Co-Chairs: Manish Aghi (SNO), Michael Vogelbaum (SCIDOT)

Session 1: Overcoming the Challenge of the BBBModerator: William Elmquist

8:10-8:30am Overcoming the BBB William Elmquist

8:30-8:50am Considerations in the design of novel small molecule drugs for brain cancer Timothy Heffron

8:50-9:10am Phase 0/2 trials Nader Sanai

9:10-9:30am Novel formulations for penetrating the BBB/BSCB Rachael Sirianni

9:30-9:50am Projecting optimal test molecule exposures for CED-based neuro-oncology studies Christopher Shaffer

9:50-10:05am BREAK

Session 2: Clinical Trials of Direct Delivery for Gliomas: Part 1Moderator: Mark Souweidane

10:05-10:25am Real-time imaging of CED Russell Lonser

10:25-10:45am Update on the MDNA55 program Krystof Bankiewicz

10:45-11:05am Update on the CAPTIVE/Keynote-192 study Frank Tufaro

11:05-11:25am Is CED a logical therapeutic strategy in brain stem gliomas of childhood? Mark Souweidane

11:25-11:45am Durable response rate in high grade glioma: An emerging endpoint for immunotherapeutics Timothy Cloughesy

11:45-12:00pm Intermittent delivery of chemotherapy in pediatric brainstem gliomas Steven Gill

12:00-1:00pm LUNCH

P R E - C O N F E R E N C E S E S S I O N S Wednesday, November 15, 2017 I Therapeutic Delivery to the CNS

Session 3: Clinical Trials of Direct Delivery for Gliomas: Part 2Moderator: Manfred Westphal

1:00-1:20pm Update on viral gene therapy program E. Antonio Chiocca

1:20-1:40pm Update on the Herpes simplex oncolytic vector program James Markert

1:40-2:00pm Update on first in human trial for a novel, multiple microcatheter CED device Michael Vogelbaum

2:00-2:20pm Pre-clinical evaluation of convection enhanced delivery platforms in a spontaneous canine glioma model John Rossmeisl

2:20-2:40pm Development of radiotherapeutic RNL186 for brain tumors Andrew Brenner

2:40-2:50pm Cerebral intraarterial chemotherapy in the treatment of malignant gliomas: ready to rise again SCDT- 21 David Fortin

2:50-3:00pm Phase I trial of a convection-enhanced delivery of nimustine hydrochloride (ACNU) for patients SCDT-29 with brainstem recurrent glioma Ryuta Saito

3:00-3:15pm BREAK

Session 4: Novel Agents for Local DeliveryModerator: Russell Lonser

3:15-3:35pm Development of liposomal irinotecan Manish Aghi

3:35-3:55pm Development of nanoparticle formulations for CED Young Seo

3:55-4:15pm Single-cycle convection enhanced delivery of a combination immunotherapy for high grade glioma Anne-Marie Carbonell

4:15-4:35pm Development of multi-targeted cytotoxic agents Waldemar Debinski

4:35-4:55pm Development of a parvovirus based immunotherapy Wolfgang Wick

4:55-5:05pm Phase I clinical trial on systemic PD-1 blockade in combination with direct intra-tumoral injection SCDT-13 of CTLA-4/PD-1 immune checkpoint inhibition following resection of recurrent glioblastoma Johnny Duerinck

5:05-5:15pm Modulation of convection enhanced delivery (CED) distribution using focused ultrasound (FUS) SCDT-37 Melanie Schweitzer

5:15-7:15pm POSTER AND NETWORKING RECEPTION

P R E - C O N F E R E N C E S E S S I O N S Thursday, November 16, 2017 I Therapeutic Delivery to the CNS


Session 5: New Strategies in Interstitial DeliveryModerator: Raghu Raghavan

8:00-8:20am Critical review of ultrasound enhanced convective delivery Raghu Raghavan

8:20-8:40am Pulsed focused ultrasound - priming of the brain interstitium for convection-enhanced delivery David Hersh

8:40-9:00am Intra-tumor infusions in liver and imaging Eleni Liapi

9:00-9:20am Glymphatics for delivery Jeffrey Iliff

9:20-9:40am Large volume infusions William Broaddus

9:40-10:00am Drug delivery for intracerebral hemorrhage Wally Block

10:00-10:15am BREAK

Session 6: Clinical Trials for Neurodegenerative DisordersModerator: Krystof Bankiewicz

10:15-10:35am Intermittent convection enhanced delivery of GDNF in Parkinson’s disease Steven Gill

10:35-10:55am Stem cell delivery for ALS Nicholas Boulis

10:55-11:15am Therapeutic development for Huntington’s Disease Lee Henderson

11:15-11:35am Treatment of AADC deficiency in children Krystof Bankiewicz

11:35-11:45am Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents SCDT-02 Choi-Fong Cho

11:45-11:55am Time-dependent activation of adenosine A2A receptor disrupts cytoskeleton and tight junctions SCDT-34 in brain microvascular cells to enhance paracellular permeability Amelie Vezina

12:00-1:00pm LUNCH

Session 7: New Approaches, Part 1Moderator: Waldemar Debinski

1:00-1:20pm The many facets of transcranial focused ultrasound Jeffrey Elias

1:20-1:40pm Stem cell therapeutics and ultrasound Akiva Mintz

1:40-2:00pm Therapeutic use of ultrasound in cancer Constantin Coussios

P R E - C O N F E R E N C E S E S S I O N S Thursday, November 16, 2017 I Therapeutic Delivery to the CNS

2:00-2:20pm LITT for treating neurological diseases Gene Barnett

2:20-2:30pm Enhancement of drug penetration into brain tumors with focused ultrasound-induced blood- SCDT-33 tumor barrier disruption Costas D. Arvanitis

2:30-2:40pm Stem cell loaded oncolytic viruses track and kill metastatic brain tumors SCDT-26 Khalid Shah

2:40-2:50pm Safety and efficacy of intraventricular 131I-labeled monoclonal antibody 8H9 targeting the SCDT-38 surface glycoprotein B7-H3 in patients with CNS/LM disease Kim Kramer

2:50-3:05pm BREAK

Session 8: New Approaches, Part 2Moderator: Zvi Ram

3:05-3:20pm TBD Deep Singh

3:20-3:40pm Development of a novel CED catheter Christopher Rylander

3:40-4:00pm Development of new CED devices Owen Lewis

4:00-4:20pm Tumor treating fields for glioma Roger Stupp

4:20-4:40pm Point source electroporation Yael Mardor

4:40-4:50pm Focal enhanced delivery of systemically administered therapeutic human mesenchymal stem SCDT-09 cells using MRI-guided disruption of the BBB with focused ultrasound Rawan Al-kharboosh

4:50-5:00pm Nanobioconjugates crossing BBB for delivery of checkpoint inhibitors and activation of local brain SCDT-39 tumor immune systems for glioma treatment Julia Ljubimova

5:00-5:10pm Value of T2-weighted MR imaging to evaluate drug distribution the brain stem of children SCDT-49 Mark Souweidane

5:10pm ADJOURN

E D U C AT I O N D AY P R O G R A MThursday, November 16, 2017 I SNO Education Day

Education Day Co-chairs: Susan Bell, Robert Cavaliere, Albert Kim, Khalid Shah

7:00-8:00am LIGHT CONTINENTAL BREAKFAST

CONCURRENT BREAKOUT SESSIONTUMOR BIOLOGY AND THERAPYBiology of ResistanceModerators: Albert Kim, Khalid Shah

9:30-9:55am Intrinsic vs. acquired resistance in cancer Maurizio Scaltriti

9:55-10:20am Subclonal architecture and therapeutic implications in glioblastoma Albert Kim

10:20-10:45am The impact of tumor metabolic reprogramming on therapeutic resistance Paul Mischel

10:45-11:10am Immune resistance and suppression mechanisms in brain tumors Gavin Dunn

11:10-11:35am Role of macrophages and microglia in tumor progression David Gutmann

11:35-12:35pm LUNCH

CONCURRENT BREAKOUT SESSIONPRACTICAL AND APPLIED NEURO-ONCOLOGYSurvivorship and Measuring Outcomes Moderators: Susan Bell, Robert Cavaliere

9:30-9:55am Survivorship and brain tumors: wishful thinking or a daily reality? Robert Cavaliere

9:55-10:20am Application and interpretation of patient reported outcomes in clinical research Jeffrey A. Sloan

10:20-10:45am SISAQOL initiative in neuro-oncology Martin Taphoorn

10:45-11:10am Development and implementation of neuro- oncology survivorship care plans Heather Leeper

11:10-11:35am Quality of life issues in meningioma patients Linda Dirven

MORNING JOINT SESSION

8:00-8:10am Welcome and Introduction Susan Bell, Robert Cavaliere, Albert Kim, Khalid Shah

8:10-8:40am Keynote Presentation: Emerging principles of therapeutic resistance in cancer Trever Bivona

8:40-9:10am Keynote Presentation: Integrative cancer care Donald I Abrams

9:10-9:30am BREAK

E D U C AT I O N D AY P R O G R A MThursday, November 16, 2017 I SNO Education Day

M A I N M E E T I N G P R O G R A MFriday, November 17, 2017

AFTERNOON JOINT SESSION

3:00-3:30pm Keynote Presentation: Impact of self-reported outcomes on early detection of late effects among survivors of childhood cancer Gregory Armstrong

3:30-4:00pm Keynote Presentation: Different facets of resistance and their implications on the future of neuro-oncology E. Antonio Chiocca

4:00-4:30pm Panel Discussion: Therapy resistance Trever Bivona, Paul Mischel, Maurizio Scaltriti, Jann Sarkaria

4:30-5:00pm Panel Discussion: Burnout in neuro-oncology practitioners Terri Armstrong, Barbara O’Brien, Shlomit Yust-Katz, Alvina Acquaye

5:00pm ADJOURN

AFTERNOON CONCURRENT BREAKOUT SESSION TUMOR BIOLOGY AND THERAPYTherapy-specific Resistance MechanismsModerators: Albert Kim, Khalid Shah

12:35-1:00pm Understanding TMZ resistance and advancing strategies for sensitization in glioblastoma Jann Sarkaria

1:00-1:25pm Chemo-resistance driven by the vascular niche in cancer Shahin Rafii

1:25-1:50pm Principles of radiation resistance in glioblastoma Erik Sulman

1:50-2:15pm Molecular mechanisms of resistance to immune checkpoint inhibitors Roger Lo

2:15-2:40pm Overcoming tumor resistance via engineering novel biological therapies Khalid Shah

2:40-3:00pm BREAK

AFTERNOON CONCURRENT BREAKOUT SESSION PRACTICAL AND APPLIED NEURO-ONCOLOGYMitigating Effects of Treatment and Disease Moderators: Susan Bell, Robert Cavaliere

12:35-1:00pm Ketogenic diet in the management of brain tumors Adrienne Scheck

1:00-1:25pm Nutrition for cancer patients Leonora Renda

1:25-1:50pm Current landscape of otoprotection chemotherapy-induced ototoxicity Susan Lindemulder

1:50-2:15pm Sleep and wake disturbances, fatigue and insomnia in cancer patients Ann Berger

2:15-2:40pm Care of the caretaker Suzanne Kisylia

WELCOME RECEPTION

Young Investigator’s Career Development and Networking Session (Pre-registration required. See SNO website for further details.)

7:30-10:00pm

7:30-8:30pm

ACTR Adult Clinical Trials - Non-ImmunologicANGI Angiogenesis and InvasionATIM Adult Clinical Trials - ImmunologicCBIO Cell BiologyCMET CNS MetastasisCSIG Cell Signaling and Signaling PathwaysDDIS Drug DiscoveryDRES Drug ResistanceEPID EpidemiologyEXTH Experimental Therapeutics - Non-ImmunologicalGENE Genetics and Epigenetics

HOUT Health Outcome MeasuresIMMU ImmunologyMETB MetabolomicsMNGI MeningiomaNCMP Neurological Complications of CancerNCOG Neuro-Cognitive OutcomesNIMG NeuroimagingNTOX Neurotoxicity of Cancer TreatmentPALL Supportive Palliative CarePATH Molecular Pathology and Classification - Adult and PediatricPDCT Pediatric Clinical Trials and Outcomes

ABSTRACT CODESPDTM Pediatric Tumors-non-immunologicalQLIF Quality of LifeRARE Rare TumorsRBIO RadiobiologyRTHP Radiation TherapySTEM Stem CellsSURG Surgical TherapyTMIC Tumor MicroenvironmentTMOD Tumor Models


7:00-8:30am SUNRISE SESSIONS


ASNO/SNO Joint Session: New Horizon in PET Imaging in Neuro-oncology Shin-Ichi Miyatake (Chair)

• Role of amino acid-tracer PET for decision making in neuro-oncologyJoerg-Christian Tonn

• Usefulness of positron emission tomography (PET) for CNS tumorsKeisuke Miyake

• Feedback of the PET-imaging to the treatment of malignant brain tumors and radiation injuriesShin-Ichi Miyatake

• Simultaneous PET/MRI in clinical neuro-oncologyIan Law

A “Vagabond Theory” of Glioblastoma: Picking One’s Way Through the Brain Microenvironment to Fatal Progression Michael Berens (Chair)

• From niche to milieuMichael Berens

• Macro effects of microglia and macrophagesJoanna Phillips

• Cloak and daggerJustin Lathia

• Inside out-the making of the microenvironment of glioblastomaJakub Godlewski

Immune Based Therapies for GliomaDuane Mitchell (Chair)

• Cellular immunotherapy targeting glioblastomaDuane Mitchell

• Checkpoint inhibitors for malignant gliomasMichael Lim

• Immunotherapy targeting glioma neoantigensHideho Okada

• Overcoming immunosuppression in malignant gliomasDerek Wainwright

Therapeutic Opportunities Presented by Dysregulated Cell Signaling MechanismsFrank Furnari (Chair)

• Leaders and followers in brain tumor heterogeneityFrank Furnari

• Regulatory circuits in GBM subtypesShi-Yuan Cheng

• Next-generation therapies to treat driver pathways in glioblastomaWilliam Weiss

• Metabolic signaling and epigenetic regulation in gliomaZhimin Lu

Current Update on the Diagnosis and Management of Lower Grade GliomasDaniel Brat (Chair)

• Contemporary molecular classification of lower grade gliomas with implications for diagnosis and gradingDaniel Brat

• Intraoperative IDH status determining extent of resection and outcomeGelareh Zadeh

• Title TBDElizabeth Maher

• Ancestry of multifocal lower grade gliomasJoseph Costello

Getting More Out of Radiation: Combination Therapy and Dose EscalationErik Sulman (Chair)

• Mechanisms to improve the effect of radiationErik Sulman

• Blood brain barrier penetration in radio-sensitivityJann Sarkaria

• Escalating the dose to improve the outcome of patients with glioblastomaChristina Tsien

• Multi-arm adaptive trials to improve the efficacy of radiationBrian Alexander


Scientific Meeting Co-Chairs: Manish Aghi, Frank Furnari, Vinay Puduvalli

9:00-12:00pm FRIDAY PLENARY SESSION

9:00-9:05am Welcome and Introduction of Scientific Program Manish Aghi, Frank Furnari, Vinay Puduvalli

9:05-9:35am Keynote Presentation: Introduction to the Moonshot Program W.K. Alfred Yung

9:35-10:05am Keynote Presentation: Advancing science from discovery lab to strategic teamwork: an NINDS perspective Walter Koroshetz

10:05-10:35am Keynote Presentation: Signatures of mutational processes in human cancer Ludmil Alexandrov

10:35-10:50am BREAK

10:50-11:05am Mutant IDH1 co-operates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in CSIG-08 glioma Mukherjee J, Johannessen T, Ohba S, Chow T, Jones L, Pandita A, Pieper R ADULT BASIC RESEARCH AWARD AND ANDREW PARSA YOUNG INVESTIGATOR AWARD

11:05-11:20am Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed ACTR-58 MGMT-methylated glioblastoma patients: the CeTeG/NOA-09 trial Herrlinger U, Tzaridis T, Mack F, Steinbach J, Schlegel U, Sabel M, Hau P, Kortman R, Krex D, Grauer O, Goldbrunner R, Schnell O, Baehr O, Uhl M, Tabatabai G, Ringel F, Schmidt-Graf F, Brehmer S, Weyerbrock A, Bullinger L, Vajkoczy P, Vatter H, Schäfer N, Kebir S, Weller J, Stummer W, Simon M, Keil V, Nelles M, Fimmers R, Pietsch T, Hattingen E, Coch C, Glas M ADULT CLINICAL RESEARCH AWARD

11:20-11:35am AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: ACTR-46 updated results from the phase 1 non-enhancing glioma population Mellinghoff I, Touat M, Maher E, De La Fuente M, Cloughesy T, Holdhoff M, Cote G, Burris H, Janku F, Huang R, Young R, Ellingson B, Nimkar T, Jiang L, Ishii Y, Choe S, Fan B, Steelman L, Yen K, Bowden C, Pandya S, Wen P ADULT CLINICAL RESEARCH AWARD

11:35-11:50am Comprehensive genomic characterization of aggressive meningiomas identifies molecular signatures that predict GENE-04 clinical outcomes Vasudevan H, Braunstein S, Phillips J, Pekmezci M, Wu A, Reis G, Magill S, Chang S, Sneed P, McDermott M, Perry A, Raleigh D ADULT BASIC RESEARCH AWARD

11:50-11:55am Memorial Tribute to Jan Esenwein: Charles Haynes

11:55-12:00pm Jan Esenwein Public Service Award Recipient: Carol Kruchko

12:15-1:15pm LUNCH

LUNCHTIME TUTORIALS AND EDUCATIONAL SESSIONSNot sponsored by The University of Texas MD Anderson Cancer Center

Epigenetics of CNS MalignanciesHoutan Noushmehr (Chair)• Defining the non-coding epigenome of glioma CpG island methylator phenotype (G-CIMP), Houtan Noushmehr• Disentangling developmental and oncogenic epigenetic states of medulloblastoma subtypes, Paul Northcott• Histone modifications in pediatric gliomas, Sriram Venneti

12:15-1:15pm LUNCH, continued

Palliative Care-Health Outcome Measures and Communication Strategies in Neuro-OncologyTobias Walbert (Chair)• Introduction to palliative care in neuro-oncology and health outcome measures, Tobias Walbert• Communication strategies in neuro-oncology, Alan Carver• Palliative care integration into neuro-oncology, Jennifer Philip

Emerging Functional and Genomic Single Cell TechnologiesKeith Ligon (Chair)• Single cell mass as a novel biomarker of drug response in brain tumors, Keith Ligon• Single cell cloning analysis of tumors and their treatment hierarchies using optical bar coding, Katrin Lamszus• EvoSeq: A molecular time machine to characterize resistance at a single cell level, Pratiti “Mimi” Bandopadhayay

Clinical Trials - A Primer for Junior InvestigatorsPatrick Wen (Chair)• Design of phase 0 and I trials, Patrick Wen• Design of phase II trials, Timothy Cloughesy• Basic statistics for clinical trial design, Karla Ballman

Industry Supported SymposiaNot sponsored by The University of Texas MD Anderson Cancer Center • Incorporating new strategies: current and future directions in glioblastoma management


1:30-5:00pm CONCURRENT SESSIONS

CONCURRENT SESSION 2AAdult Clinical Trials I Moderators: Timothy Cloughesy, Warren Mason

1:30-1:40pm Introduction Burt Nabors

1:40-1:55pm Multicenter, phase 2 study of bevacizumab RARE-19 in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: an NF Clinical Trials Consortium study Plotkin S, Tonsgard J, Ullrich N, Allen J, Blakeley J, Rosser T, Campian J, Clapp W, Fisher M, Cutter G, Korf B, Packer R, Thomas C, Karajannis M

1:55-2:10pm Full enrollment results from the phase ACTR-71 1/2, multicenter, open-label study of marizomib (MRZ) ± bevacizumab (BEV) in recurrent WHO grade IV malignant glioma (glioblastoma, rGBM) Bota D, Desjardins A, Mason W, Kesari S, Magge R, Winograd B, Reich S, Levin N, Trikha M

2:10-2:25pm Intravenous delivery of Toca 511 in patients ATIM-21 with high grade glioma results in quantifiable expression of cytosine deaminase in tumor tissue Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aquirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T

2:25-2:40pm Dose dense temozolomide (TMZ) as initial ACTR-06 treatment for high-risk oligodendroglial tumors: long-term results of a Phase II AINO (Italian Association for Neuro-Oncology) study Soffietti R, Pellerino A, Pace A, Carapella C, Dealis C, Caroli M, Faedi M, Bello L, Rudà R

2:40-2:50pm Hypoxia activated evophosphamide (TH-302)ACTR-95 for recurrent GBM following bevacizumab failure, a multicenter phase II study Brenner A, Reardon D, Wen P, Fox P, Huang S, Muzi M, Liu Y, Lee E

2:50-3:00pm Predictive significance of IDH1/2 mutation ACTR-37 and 1p/19q co-deletion status in a post-hoc analysis of NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high risk low-grade gliomas Bell E, Zhang P, Shaw E, Buckner J, Barger G, Coons S, Bullard D, Mehta M, Gilbert M, Brown P, Stelzer K, Fleming J, McElroy J, Timmers C, Becker A, Salavaggione A, Liu Z, Aldape K, Brachman D, Gertler S, Murtha A, Schultz C, Johnson D, Shu H, Chakravarti A

3:00-3:15pm BREAK


CONCURRENT SESSION 2BSurgery/Radiation/RadiobiologyModerators: Fen Xia, Bradley Elder

1:30-1:40pm A comprehensive genomic landscape of gliomaTMOD-04 spheroid cultures recapitulates the heterogeneity of glioblastoma and identifies DNA methylation predictors of radiotherapy response Wang Q, Ezhilarasan R, Goodman L, Eskilsson E, Yang J, Gumin J, Zheng S, Tang M, Jaffari M, Long L, Yoshihara K, Sun P, Heffernan T, Yung W, Draetta G, Aldape K, Lang F, Verhaak R, Sulman E

1:40-1:50pm A 40-year multi-institutional review of RTHP-31 intracranial germ cell tumors in adolescents and young adult Lo A, Goddard K, Hodgson D, Dang J, Tyldesley S, Bouffet E, Bartels U, Cheng S, Hukin J, Bedard P, Tran J, Laperriere N

1:50-1:55pm Post-surgical, residual enhancing tumor NIMG-53 volume is prognostic for overall survival in newly diagnosed glioblastoma: Evidence from 1,458 patients pooled from international trials, single institution databases, and multicenter consortiums Ellingson B, Abrey L, Nelson S, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason W, Wick W, Butowski N, Ligon K, Gerstner E, Colman H, de Groot J, Chang S, Mellinghoff I, Young R, Colen R, Taylor J, Arrillaga-Romany I, Huang R, Pope W, Reardon D, Batchelor T, Wen P, Prados M, Cloughesy T

1:55-2:00pm Convection enhanced delivery of topotecan SURG-10 and gadolinium for recurrent GBM via the Cleveland Multiport Catheter: A first in human study Vogelbaum M, Mohammadi A, Brewer C, Peereboom D, Ahluwalia M

2:00-2:05pm CSF-1R inhibition ameliorates radiation-RBIO-03 induced memory loss in a rodent glioma model Feng X, Grue K, Liu S, Gupta N, Rosi S

2:05-2:10pm The impact of surgery in molecularly defined SURG-05 low-grade glioma: an integrated clinical, radiological and molecular analysis Wijnenga W, French P, Dubbink H, Dinjens W, Atmodimedjo P, Kros J, Smits M, Gahrmann R, Rutten G, Verheul J, Fleischeuer R, Dirven C, Vincent A, van den Bent M

2:10-2:15pm Subcortical stimulation mapping of descendingSURG-03 motor pathways for perirolandic gliomas: Assessment of morbidity and functional outcome in over 700 patients Han S, Troncon I, Morshed R, Jordan K, Henry R, Berger M

2:15-2:20pm Pediatric radiation-induced glioblastoma: PDTM-01 transcriptomic and drug screening analysis of primary patient samples DeSisto J, Donson A, Flannery P, Lemma R, Sanford B, Foreman N, Vibhakar R, Jones K, Green A

2:20-2:25pm A prospective phase II randomized trial to ACTR-72 compare intensity modulated proton radiotherapy (IMPT) vs. intensity modulated radiotherapy (IMRT) for newly diagnosed Glioblastoma (GBM) Chung C, Brown P, McAvoy S, Grosshans D, Dibaj S, Guha-Thakurta N, Li J, McGovern S, Mcaleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, de Groot J, Heimberger A, Armstrong T, Gilbert M, Mahajan A, Wefel J

2:25-2:30pm TIE2-mediated epigenetic modifications GENE-19 regulate radioresistance of glioblastoma Hossain M, Shifat R, Rivera-Molina Y, Puerta- Martinez F, Jiang H, Kim D, Johnson D, Bedford M, Sulman E, Lang F, Fueyo J, Gomez-Manzano C

2:30-2:35pm Histopathologic features predict local control MNGI-09 after adjuvant radiotherapy for atypical meningioma Chen W, Magill S, Wu A, Vasudevan H, Aghi M, Theodosopoulos P, Perry A, McDermott M, Sneed P, Braunstein S, Raleigh D

2:35-2:40pm High-risk meningioma: Initial outcomes from MNGI-08 NRG Oncology/RTOG-0539 Rogers L, Zhang P, Vogelbaum M, Perry A, Ashby L, Modi J, Alleman A, Galvin J, Fogh S, Youssef E, Deb N, Kwok Y, Robinson C, Shu H, Fisher B, Panet-Raymond V, McMillan W, de Groot J, Mehta M

2:40-2:45pm Prognostic factors, treatment and outcome RARE-15 in patients with intracranial hemangioblastoma: a study of 3449 patients from the National Cancer Data Base Chan L, Bai H, Huang Y, Li X, Liao W, Cao Y, Karakousis G, Huang R, Xiao B, Zhang P, Yang L

2:45-2:50pm Feasibility and safety of surgical biopsy for PDCT-20 patients with DIPG: preliminary results from DIPG-BATS Gupta N, Goumnerova L, Ayyanar K, Gump W, Bendel A, Nagib M, Bowers D, Weprin B, Bredlau A, Gururangan S, Fuchs H, Cohen K, Jallo G, Dorris K, Handler M, Comito M, Dias M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Gardner S, Karajannis M, Harter D, Gauvain K, Limbrick D, Leonard J, Geyer J, Leary S, Browd S, Khatib Z, Ragheb J, Bhatia S, MacDonald T, Aguilera D, Brahma B, Manley P, Chi S, Mueller S, Banerjee A, Murray J, Nazemi K, Baird L, Robison N, Kiehna E, Krieger M, Sandler E, Aldana P, Wang J, Sood S, Neuberg D, Puligandla M, Greenspan L, Wright K, Prados M, Bandopadhayay P, Ligon K, Kieran M

2:50-2:55pm Results of phase I of the PARADIGM trial: ACTR-22 a phase I dose escalation study of olaparib in combination with short course radiotherapy in elderly patients with newly diagnosed glioblastoma (GBM) Chalmers A, Stobo J, Short S, Herbert C, Saran F, Morris A, Dillon S, Kelly C

2:55-3:00pm Discussion

3:00-3:15pm BREAK


CONCURRENT SESSION 2CExperimental Therapeutics and Tumor ModelsModerators: William Weiss, Jann Sarkaria

1:30-1:35pm Discovery of CT-179: a small molecule EXTH-08 inhibitor of the OLIG2 transcription factor with potent anti-tumour activity in high- grade glioma Johns T

1:35-1:40pm PLX51107, a novel bromodomain inhibitor, PDTM-15 works synergistically with AURORA-A kinase inhibitor MLN8327 in treating MYC- amplified medulloblastoma Wadhwa E, Zhang J, Powell B, Van C, Gustafson C, Nicolaides T 1:40-1:45pm Zika virus targeting of malignant human and EXTH-01 murine brain tumors Shiao M, Bierle C, Chrostek M, Crane A, Danczyk G, Miller Z, Pearce C, Schaible K, Schleiss M, Sipe C, Straub E, Toman N, Vaid S, Voth J, Low W

1:45-1:50pm Combined intracavitary thermotherapy SURG-32 with iron-oxide nanoparticles and radiotherapy as a promising treatment modality in recurrent GBM Grauer O, Jaber M, Hess K, Weckesser M, Maring S, Schwindt W, Stummer W, Wölfer J

1:50-1:55PM MEK kinase inhibitor, trametinib, suppresses EXTH-17 macrophage-secreted TNF-α on oncolytic HSV-1 therapy, enhancing virotherapy Yoo J, Lee T, Liu J, Jaime-Ramirez A, Weiss A, Russell L, Nallanagulagari T, Zhang J, Kaur B 1:55-2:00pm GD2-directed chimeric antigen receptor T PDTM-39 cells as a potent immunotherapy regimen in xenograft models of diffuse intrinsic pontine glioma Mount C, Majzner R, Sundaresh S, Arnold E, Kadapakkam M, Monje-Deisseroth M, Mackall C

2:00-2:05pm A precision medicine approach to target EXTH-46 EGFRvIII in GBM: Osimertinib (AZD9291) inhibits the growth of EGFRvIII-positive glioblastoma stem cells and increases survival of mice bearing intracranial EGFRvIII- positive GBM Kwatra M, Nanni C, Roberts C, Kwatra S, Gilbert M, Lesser G

2:05-2:10pm Application of a functional genetics approach DDIS-21 to identify pharmacological inhibitors of HIF-1 α Qi Q, Johannessen T-C, Wang J, Li X, Bjerkvig R, Prestegarden L

2:10-2:15pm TG02, a novel targeting of transcription and EXTH-62 metabolism in glioblastoma Su Y, Chen R, Song H, Zhang Q, Li A, Celiku O, Meetze K, Estok T, Maric D, Zhuang Z, Yang C, Zhang W, Gilbert M, Wu J

2:15-2:20pm A cancer drug-atlas enables prediction of EXTH-06 parallel drug vulnerabilities Narayan R, Molenaar P, Cornelissen F, Roelofs I, Sminia P, Wurdinger T, Koster J, Westerman B

2:20-2:25pm An engineered microRNA cluster for broad EXTH-69 targeting of epigenetic complexes in GBM Bhaskaran V, Idriss M, Lawler S, Chiocca E, Peruzzi P

2:25-2:30pm Differentiated pharmacology of the EXTH-43 imipridone ONC201, the first selective DRD2/3 antagonist in clinical neuro-oncology Madhukar N, Prabhu V, Anantharaman L, Sulli C, Davidson E, Deacon S, Tarapore R, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free R, Sibley D, Allen J

2:30-2:35pm Imaging glioblastoma stem cells with EXTH-75 7-amino acid-length tumor-homing peptide identified by phage display biopanning Kim J, Rich J, Liu J

2:35-2:40pm Human pluripotent stem cell-based models TMOD-09 of neuroblastoma Huang M, Zheng T, Guo J, Sperring C, Miller M, McHenry L, Zhen Q, Moriarity B, Bronner M, Conklin B, Largaespada D, Maris J, Matthay K, Weiss W

2:40-2:45pm MYCN overexpression and stabilization drives TMOD-05 medulloblastoma from human neuro- epithelial stem cells Čančer M, Hutter S, Rosén G, Hellström A, Essand M, Huang M, Tailor J, Smith A, Weiss W, Falk A, Weishaupt H, Swartling F

2:45-2:50pm Pre-clinical safety and efficacy studies of STEM-32 neural stem cell mediated carboxylesterase/ irinotecan enzyme/prodrug gene therapy for recurrent glioma leading to first-in-human phase I clinical trial Ghoda L, Metz M, Tirughana R, Aramburo S, Gilchrist M, Gutova M, Synold T, Barish M, Brown C, D’Apuzzo M, Moats R, Potter P, Blanchard S, Portnow J, Aboody K


3:00-3:15pm BREAK


CONCURRENT SESSION 3AAdult Clinical Trials IIModerators: David Piccironi, Mustafa Khasraw

3:15-3:20pm Therapeutic targeting of tumorigenic IMMU-03 EphA2+/EphA3+ brain tumor initiating cells with bispecific antibody in human glioblastoma Qazi M, Vora P, Venugopal C, Gorelik M, Singh M, Hu A, Subapanditha M, Chokshi C, Savage N, Yelle N, Adams J, Moffat J, Sidhu S, Singh S

3:20-3:25pm A phase I trial of hypofractionated ATIM-18 stereotactic irradiation (HFSRT) with pembrolizumab and bevacizumab in patients with recurrent high grade glioma (NCT02313272) Sahebjam S, Forsyth P, Arrington J, Jaglal M, Tran N, Etame A, Wicklund M, Drury-Sibiga A, Long W, Evernden B, Gatewood T, Macaulay R, Chinnaiyan P, Yu M

3:25-3:30pm Multicenter pilot study of radio-RARE-10 chemotherapy as first-line treatment for adults with medulloblastoma – the NOA-07 trial Beier D, Proescholdt M, Pietsch T, Jones D, Pfister S, Hattingen E, Dirven L, Lürding R, Weller M, Kortman R, Bogdahn U, Hau P

3:30-3:35pm A phase 1, multicenter, open-label study of ACTR-45 marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM) Bota D, Mason W, Kesari S, Piccioni D, Aregawi D, Desjardins A, Winograd B, Reich S, Levin N, Trikha M

3:35-3:40pm Final results from a phase I study of ACTR-76 plerixafor and bevacizumab in recurrent high-grade glioma Lee E, Muzikansky A, Gerstner E, Kuhn J, Reardon D, Nayak L, Norden A, Doherty L, Stefanik J, Armitage J, LaFrankie D, Ruland S, Vardam T, Stokes D, Smith K, McCluskey C, Gaffey S, Batchelor T, Jain R, Duda D, Wen P

3:40-3:45pm Durable responses observed in IDH1 wildtypeATIM-02 and mutant recurrent high grade glioma (rHGG) with Toca 511 & Toca FC treatment Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen C, Kalkanis S, Lai A, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago O, Hogan D, Jolly D, Wood K, Yang L, Gruber H, Das A, Walbert T

3:45-3:50pm Concordance of EGFR and MGMT analyses ACTR-68 between local and central laboratories: implications for clinical trial design and precision medicine for depatuxizumab- mafodotin (ABT-414) in glioblastoma (GBM) Lassman A, Dimino C, Mansukhani M, Murty V, Ansell P, Bain E, Holen K, Roberts-Rapp L, Lee J, Curran W, Mehta M, Canoll P

3:50-3:55pm Clinical impact of TERT promoter detection in ACTR-52 circulating cell-free DNA of patients with glioblastoma – a pilot study Juratli T, Stasik S, Richter S, Zolal A, Schackert G, Krex D, Thiede C

3:55-4:00pm Plasma and tumor pharmacokinetics of ACTR-67 Ribociclib in patients with recurrent glioblastoma Tien A, Bao X, DeRogatis A, Higginbotham L, Honea N, Mehta S, Li J, Sanai N 4:00-4:05pm A phase II study of the efficacy of ACTR-88 hypofractionated radiation therapy with bevacizumab and temozolomide followed by maintenance temozolomide and bevacizumab for recurrent high-grade gliomas Dixit K, Kumthekar P, Kruser T, Sachev S, Kalapurakal J, Gondi V, Grimm S, Nicholas M, Lukas R, Chmura S, Mehta M, Raizer J

4:05-4:10pm Does Levetiracetam act as a Ttmozolomide SURG-30 chemosensitizer in patients with glioblastoma? Roh T, Kim S, Kang S, Kim E, Cho J, Suh C, Chang J

4:10-4:15pm Results of the OPARATIC trial: a phase I dose ACTR-16 escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM) Chalmers A, Cruickshank G, Dunn L, Erridge S, Godfrey L, Herbert C, Jefferies S, Lopez J, McBain C, Pittman M, Sleigh R, Watts C, Webster-Smith M, Halford S

4:15-4:20pm Compliance and treatment duration predict ACTR-27 survival in a phase 3 EF-14 trial of tumor treating fields with temozolomide in patients with newly diagnosed glioblastoma Ram Z, Kim C, Nicholas G, Toms S

4:20-4:25pm Advanced MRI assessment during dendritic NIMG-25 cell immunotherapy Eoli M, Cuccarini V, Aquino D, Anghileri E, Pellegatta S, Finocchiaro G, Bruzzone M

4:25-4:30pm A phase I study of MLN0128 (TAK-228) and ACTR-93 bevacizumab in patients with advanced solid tumors including glioblastoma Nayak L, Hays J, Do K, Muzikansky A, Gaffey S, Lee E, Rinne M, Norden A, Beroukhim R, Puduvalli V, Wen P, Doyle L, Chen H, Shapiro G, Reardon D

4:30-4:35pm Safety and efficacy evaluation of a phase II ACTR-53 study of bortezomib in combination with temozolomide and regional radiation therapy for upfront treatment of patients with newly-diagnosed glioblastoma multiforme (GBM) Kong X, Nguyen N, Choi Y, Zhang G, Nguyen H, ilka E, Green S, Yong W, Liau L, Kaprealian T, Pope W, Nghiemphu P, Cloughesy T, Lassman A, Lai A


4:35-4:40pm Final results from the dose-escalation stage ACTR-28 of a Phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma Goldlust S, Nabors L, Mohile N, Benkers T, Hsu S, Silberman S, Singer S, Rao M, Cappello L, Farmer G

4:40-4:45pm Molecular genetic, host-derived and clinical ACTR-23 determinants of long-term survival in glioblastoma: first results from the Brain Tumor Funders’ Collaborative Consortium Happold C, Felsberg J, Clarke J, Soffietti R, Marosi C, Krex D, Ducray F, Hau P, Reijneveld J, Weyerbrock A, Wick A, Reardon D, Glas M, Razis E, Herrlinger U, Tonn J, Carpentier A, Lefranc F, Le Rhun E, Verschuere T, Golfinopoulos V, Klein M, Reifenberger G, Weller M

4:45-4:50pm Clinical evaluation of the imipridone ONC201 ACTR-51 in recurrent glioblastoma: Predictive and pharmacodynamic biomarker analyses Arrillaga-Romany I, Allen J, Prabhu V, Tarapore R, Zloza A, Oster W, Wen P, Batchelor T


CONCURRENT SESSION 3BEpigenetics/Genetics Moderators: Joseph Costello, Colin Watts

3:15-3:30pm Transcription elongation factors represent in GENE-30 vivo cancer dependencies in glioblastoma Miller T, Liau B, Wallace L, Morton A, Xie Q, Dixit D, Factor D, Kim L, Morrow J, Wu Q, Mack S, Hubert C, Paddison P, Horbinski C, Bernstein B, Tesar P, Rich J

3:30-3:40pm Atrx deficiency in glioma cells of origin GENE-24 promotes disease-defining phenotypes by way of global epigenomic remodeling Danussi C, Bose P, Parthasarathy P, Silberman P, Van Arnam J, Vitucci M, Tang O, Heguy A, Chan T, Sulman E, Lang F, Creighton C, Deneen B, Miller C, Picketts D, Kannan K, Huse J

3:40-3:50pm Peripheral blood DNA methylation profiles GENE-02 identify IDH1/2 mutation status in adults with diffuse glioma Kloetgen A, Serrano J, Patel S, Bowman C, Shen G, Zagzag D, Karajannis M, Golfinos J, Placantonakis D, Tsirigos A, S. Chi A, Snuderl M

3:50-4:00pm A novel mutation in PRKCA is the major GENE-54 driver of Chordoid Gliomas Rosenberg S, Simeonova I, Bielle F, Verreault M, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella Branger D, Aubriot-Lorton M, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Mokhtari K, Pagnotta S, Iavarone A, Lasorella A, Huillard E, Sanson M

4:00-4:10pm Generation of a mouse model of diffuse GENE-17 intrinsic pontine glioma harboring ACVR1 G328V and H3.1 K27M mutations Mendez F, Nunez F, Koschmann C, Saxena M, Kamran N, Dzaman M, Pawar S, Lowenstein P, Castro M 4:10-4:20pm Emerging principles of synthetic lethality in GENE-12 glioblastoma Hoellerbauer P, Arora S, Feldman H, Carter L, Girard E, Corrin P, Olson J, Paddison P

4:20-4:25pm Characterizing epigenetic intratumoral GENE-59 heterogeneity in glioma using single- cell reduced representation bisulfite sequencing Johnson K, Tang M, Estecio M, Robson P, Verhaak R

4:25-4:30pm Epigenetic reprogramming in mutant IDH1 GENE-58 glioma impacts median survival, enhances DNA damage response and confers radioresistance Nunez FJ, Mendez FM, Kadiyala P, Savelieff M, Koschmann C, Carney S, Patel R, Manawar S, Kamran N, Saxena M, Ljungman M, Qin T, Sator M, Dzaman M, Venneti S, Hervey-Jumper S, Figueroa MD, Lowenstein PR, Castro MG

4:30-4:35pm The origin of human glioblastoma: Firework GENE-35 pattern glioblastoma genesis from subventricular zone Kang S, Lee J, Yoon S, Park J, Kim S, Kim E, Chang J

4:35-4:40pm Chromatin accessibility defines transcriptionalGENE-11 drivers of migration in human glioblastoma Tsankova N, Erfani P, Tome-Garcia J, Nudelman G, Tsankov A, Walsh M, Zaslavsky E

4:40-4:45pm Active chromatin regulatory maps identify GENE-32 core cell state drivers of glioblastoma Mack S, Wang X, Rich J

4:45-4:50pm Unanticipated germline cancer susceptibility GENE-39 mutations identified during routine next generation sequencing of primary CNS neoplasms Lord K, Smith R, Boman C, Patel G, Thatikonda S, Burnett M, Waldron J, Kemper C, Weinberg J, Groves M

4:50-4:55pm The 3D evolution and in vivo growth patterns GENE-33 of glioma cell populations Hilz S, Shelton S, Jalbert L, Wong H, Mazor T, Hong C, Hayes J, Luks T, Bengtsson H, Molinaro A, McDermott M, Berger M, Lim D, Diaz A, Phillips J, Chang S, Nelson S, Oldham M, Costello J


Industry Supported SymposiumNot sponsored by The University of Texas MD Anderson Cancer Center • TBD

5:30-7:30pm



7:30-9:30pm E-TALKS Interactive Electronic 4 Minute Presentations Followed By Group Discussions Group 1: Cell Signaling/Genetics/Epigenetics Group 2: Drug Resistance/Experimental Therapeutics/Metabolism Group 3: Imaging/Pediatrics/Outcomes/Practical & Applied Neuro-Oncology/Pathology

7:30-9:30pm POSTER SESSION Traditional Poster Viewing

CONCURRENT SESSION 3CMicroenvironment/Angiogenesis/InvasionModerators: Michael Berens, David Gutmann

3:15-3:30pm Microenvironment-derived mitochondria TMIC-18 prime glioma chemo-resistance by potentiated NAD metabolism and base excision DNA repair Liu Y, Gilbert M, Yang C

3:30-3:40pm Glioblastoma stem cells exploit the ANGI-17 alphavbeta8 integrin-TGFbeta signaling axis to drive tumor initiation and progression McCarty J, Sulman E, Rao G, Wang Q, Lang F, Guerrero P

3:40-3:50pm Genetic driver-mutations define the TMIC-02 tumors associated macrophage composition and function in glioblastoma Chen Z, Hambardzumyan D

3:50-4:00pm High resolution RNAseq profiling of ANGI-04 glioblastoma residual invasive cells isolated by a novel 5ALA fluorescence based method Rowlinson J, Estevez-Cebrero M, Lourdusamy A, Rahman R, Smith S

4:00-4:10pm Tumor-associated neutrophils promote TMIC-10 glioblastoma growth via osteopontin in a targetable manner Yagnik G, Nguyen A, Mueller S, Alvarado B, Watchmaker P, Kriegstein A, Diaz A, Aghi M

4:10-4:15pm Direct glioma blood vessel disruption improvesANGI-11 immune therapy but worsens anti-VEGF therapy Yadav V, Kadiyala P, Zamler D, Gutierrez A, Koschmann C, Castro M, Lowenstein P

4:15-4:20pm Reprogramming the brain tumor TMIC-12 microenvironment with hematopoietic stem and progenitor cells Wildes T, Flores C, Mitchell D

4:20-4:25pm A potent microglial response to blocking TMIC-04 the CD47-Sirpα anti-phagocytic axis overcomes deficient macrophage recruitment during anti- CD47 immunotherapy against glioblastoma Hutter G, Theruvath J, Graef C, Weissman I, Mitra S, Cheshier S

4:25-4:30pm Loss of host-derived osteopontin creates a TMIC-41 glioblastoma-promoting microenvironment Szulzewsky F, Schwendinger N, Güneykaya D, Cimino P, Hambardzumyan D, Synowitz M, Holland E, Kettenmann H

4:30-4:35pm Metabolic reprogramming of the glioma IMMU-37 microenvironment inhibits tumor immunosuppression Miska J, Muroski M, Rashidi A, Chang A, Zhang P, Han Y, Lesniak M

4:35-4:40pm IL11 secretion by glioblastoma associated DRES-15 microglia define a STAT3-MYC signaling axis that is suppressed in “exceptional responders” Li J, Kaneda M, Wang J, Akers J, Ramakrishnan V, Amirfakhri S, Hirshman B, Furnari F, Jiang T, Carter B, Glass C, Ren B, Varner J, Chen C

4:40-4:45pm IDH1 mutation regulates myeloid cells IMMU-58 mediated Immunosuppression in glioma Alghamri M, Kamran N, Nunez F, Lowenstein P, Castro M

4:45-4:50pm EGFR extracellular domain point mutant EXTH-56 A289V: A therapeutically targetable driver of glioblastoma invasion Thorne A, Binder Z, Bakas S, Wileyto E, Morrissette J, Akbari H, Rathore S, Scott A, Davatzikos C, O’Rourke D, Furnari F

4:50-4:55pm Extracellular milieu in recurrent human RBIO-01 gliomas: A repertoire for novel drug development Gupta K, Burns T




7:30-9:30pm E-TALKS - GROUP 1

Cell Signaling/Genetics/EpigeneticsModerators: Milan Chheda, Renee Read

7:30pm FHL2 interacts with EGFRvIII to promote CSIG-19 glioblastoma growth Sun L, Lan Q, Li M

7:34pm Meningeal based tumors: role of STAT6 MNGI-06 expression Sahay A, Kadam V, Moiyadi A, Gupta T, Goda J, Shetty P, Jalali R, Epari S

7:38pm Pathway analysis of radiation-Induced MNGI-04 meningiomas reveals upregulation of inflammatory pathways in tumors with NF2- fusion Suppiah S, Agnihotri S, Yasin M, Zadeh G, Aldape K, Liu J

7:42pm Phosphoglycerate mutase 1 (PGAM1) CSIG-40 activates DNA damage repair via regulation of WIP1 activity Mukherjee J, Ohba S, Johannessen T, Kamalakar C, Pieper R

7:46pm miR-4516 is a novel prognostic marker and CBIO-20 promotes proliferation and invasion in glioblastoma Cui T, Bell E, McElroy J, Geurts M, Gulati P, Becker A, Fleming J, Yang L, Liu Z, Gray A, Robe P, Chakravarti A

7:50pm Use of decitabine to alter patterns of GENE-20 treatment-induced mutagenesis in glioblastoma Gallitto M, Pain M, Wang H, Deikus G, Sebra R, Yong R

7:54pm Brd4-bound stretch/super enhancer usage GENE-16 underlies sexual dimorphism in glioblastoma Kfoury N, Qi Z, Sankararaman S, Wilkinson M, Broestl L, Berrett K, Gertz J, Mitra R, Rubin J

7:58pm Discordant inheritance of chromosomal GENE-23 and extrachromosomal DNA elements contribute to dynamic disease evolution in glioblastoma deCarvalho A, Kim H, Poisson L, Koeman J, Mikkelsen T, Verhaak R

8:02pm Implications of spatial intratumoral GENE-05 mutational heterogeneity for precision medicine-guided treatment in newly diagnosed glioblastoma (GBM) Mahlokozera T, Vellimana A, Li T, Mao D, Zohny Z, Kim D, Tran D, Marcus D, Fouke S, Campian J, Dunn G, Miller C, Kim A

8:06pm Development of stable and brain-penetrating EXTH-36 disulfiram nanoparticles, characterization and efficacy in glioma cell culture and xenograft models Madala H, Punganuru S, Srivenugopal K, Ali-Osman F

8:10pm Chromothripsis leads to chromosomal GENE-44 rearrangements and gene fusions in primary glioblastomas Rousseau A, Coutolleau A, Menei P, Guardiola P, Boisselier B

8:14pm Clinical sensitivity and specificity of Illumina PATH-47 methylation array for classifying adult gliomas into WHO groups Eckel-Passow J, Decker P, Hughes E, Kollmeyer T, Kosel M, Burgenske D, Sarkaria J, Giannini C, Kipp B, Lachance D, Jenkins R

8:18pm Accurate detection of TERT promoter GENE-36 mutation in gliomas using Infinium DNA methylation arrays identifies novel epigenetic association Yang J, Wang Q, Long L, Ezhilarasan R, Sulman E

8:22pm IDH gene mutation status plays no impact on RTHP-17 survival in patients with glioblastoma at a first progression Tabei Y, Nagane M

8:26pm Clinical, molecular and radiological features PATH-12 of FGFR-TACC positive gliomas Di Stefano A, Savatovsky J, Bielle F, Alentorn A, Pïcca A, Saragoussi E, Villa C, Farina P, Lasorella A, Iavarone A, Sanson M

8:26-9:30pm Discussion in main poster area



7:30pm EZH2/PRC2-mediated epigenetic plasticity DRES-18 promotes therapeutic resistance by regulating STAT3 activation gene network in the glioma stem cells Park C, Atashi F, Caragher S, Baisiwala S, Lesniak M, James C, Ahmed A

7:34pm Primary resistance to EGFR inhibition in DRES-06 glioblastoma is mediated by a TNF-JNK-Axl- ERK signaling axis Guo G, Gong K, Habib A

7:38pm Activated Trk/Met pathway is a novel CSIG-32 resistance mechanism for CDK4/6 inhibitors that can be targeted with a specific small molecule inhibitor Olmez I, Purow B

7:42pm KIF11 as a novel therapeutic target in MNGI-01 meningioma Jungwirth G, Dettling S, Warta R, Lamszus K, Simon M, Unterberg A, Herold-Mende C

7:46pm RNA nanoparticle-based targeted gene EXTH-31 therapy for glioblastoma Lee TJ, Yoo JY, Kaur B, Croce C, Guo P

7:50pm Recurrent xenograft tumors upregulate EXTH-68 EGFR after lentiviral vector mediated suicide gene therapy for glioblastoma, but are resistant to combinatorial treatment with erlotinib Hossain J, Ystaas L, Latif A, Joseph J, Talasila K, Ninzima S, Riecken K, Fehse B, Bjerkvig R, Miletic H

7:54pm Oncolytic viral therapy with Delta24-RGD TMIC-03 induces a tumor-detrimental environment via phenotypic shift of macrophages van den Bossche W, Kleijn A, Teunissen C, Voerman J, Noske D, van Dongen J, Dirven C, Lamfers M

7:58pm The alkylating chemotherapeutic EXTH-14 temozolomide induces metabolic stress and potentiates NAD+ depletion-mediated cell death in IDH1 mutant cancers Tateishi K, Miller J, Higuchi F, V. A. Koerner M, Lelic N, Curry W, Batchelor T, Wakimoto H, S. Chi A, Cahill D

8:02pm Efficacy of the antibody-drug conjugate ABT-EXTH-39 414 in brain tumor models Muldoon L, McConnell H, Kersch C, Neuwelt E

8:06pm H3 K27M mutant gliomas are selectively EXTH-42 killed by ONC201, a small molecule inhibitor of dopamine receptor D2 Chi A, Stafford J, Sen N, Possemato R, Placantonakis D, Hidalgo ET, Harter D, Wisoff J, Golfinos J, Arrilaga-Romany I, Batchelor T, Wen P, Wakimoto H, Cahill D, Allen J, Oster W, Snude

8:10pm Development of a CRISPR-Cas9D10A DRES-04 targetable, high-complexity, single-cell barcoding approach for isolation of treatment resistant subclones from heterogenous malignant gliomas Zhang Z, Ezhilarasan R, Ding Y, Wang Q, Yang J, Long L, Verhaak R, Sulman E

8:14pm A novel bio-impedance spectroscopy system SURG-25 real-time intraoperatively discriminates glioblastoma from brain tissue in mice Zhang Y, Xu S, Min W, Shen L, Zhang Y, Yue Z

8:18pm Down-regulation of acetate metabolism METB-14 towards fatty acids in IDH1 mutant glioma Najac C, Radoul M, Viswanath P, Chaumeil M, Ronen S

8:22pm IDH3 promotes glioblastoma growth through CSIG-21 regulation of one carbon metabolism Stegh A

8:26pm GTP metabolic switch leads to nucleolar CBIO-12 transformation and malignant growth of glioblastoma Satoshi K, Hirayama A, Sakamoto N, Sumita K, Yoshino H, Warren M, Kawaguchi R, Ozawa T, Onishi N, Wolfe K, Okumura K, Ramkissoon A, Chow L, Malhotra A, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Anastasiou D, Wakimoto H, Bierhoff H, Horbinski C, Yasui W, Saya H, Soga T, Holland E, Grummt I, Mischel P, Sasaki A


Drug Resistance/Experimental Therapeutics/MetabolismModerators: Balveen Kaur, Ganesh Rao


7:30pm Multi-center study demonstrates radiomic NIMG-02 texture features derived from MR perfusion images predict pseudoprogression from true progression in glioblastoma patients Elshafeey N, Kotrotsou A, Abrol S, Hassan I, Hassan A, Agarwal A, Salek K, Bergamaschi S, Moron F, Law M, Zinn P, Colen R

7:34pm Standardized molecular analysis of primary PATH-40 central nervous system (CNS) tumors in a research based clinical practice. An introduction to the primary CNS tumor next generation sequencing (NGS) panel Siegel C, Armstrong T, Chung H, Crandon S, Patel S, Powers A, Quezado M, Ray-Chaudhury A, Vera E, Wu J, Xi L, Raffeld M, Gilbert M

7:38pm Radiologic phenotypes are treatment specific NIMG-51 and associated with survival - exploratory analysis of EORTC 26101 Nowosielski M, Gorlia T, Harting I, Radbruch A, Brandes A, Taphoorn M, Taal W, Domont J, Idbaih A, Campone M, Clement P, Stupp R, Fabbro M, Le Rhun E, von Deimling A, Platten M, Golfinopoulos V, Bendszus M, van den Bent M, Wick W

7:42pm A safety study of vemurafenib, an oral PDCT-19 inhibitor of BRAFV600E, in children with recurrent/refractory BRAFV600E mutant brain tumors: PNOC-002 Nicolaides T, Nazemi K, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Molinaro A, Mueller S, Prados M

7:46pm Volumetric 3D MR fingerprinting of adult NIMG-15 brain tumors: initial results Badve C, Kilinc O, Dastmalchian S, Ma D, Frankel S, O’Connor G, Sunshine J, Couce M, Griswold M, Gulani V, Barnholtz-Sloan J, Sloan A

7:50pm Computer based neurocognitive assessment PDCT-11 in children with central nervous system tumors treated with proton beam radiotherapy Contreras J, Stowe H, Dewees T, King A, Heimos H, Mccommis L, Perkins S

7:54pm Texture analysis of MR fingerprinting in adult NIMG-90 brain tumors Badve C, Dastmalchian S, Kilinc O, McGivney D, Ma D, Griswold M, Sunshine J, Gulani V, Barnholtz- Sloan J, Sloan A

7:58pm H3F3A and TERT promoter mutations are PATH-34 poor prognosticators in pediatric low-grade gliomas Li K, Yang R, Chan A, Chung N, Shi Z, Wu J, Ng H

8:02pm Volumetric analysis of IDH-mutant low-NIMG-50 grade glioma: A natural history study of tumor growth rates before and after treatment Huang R, Young R, Ellingson B, Veeraraghavan H, Wang W, Luks T, Kim J, Gerstner E, Schiff D, Peters K, Mellinghoff I, Chang S, Cloughesy T, Wen P

8:06pm Primary central nervous system lymphoma in RARE-05 immunocompromised hosts – a single institution retrospective study (2002-2017) Kaulen L, Galluzzo D, Hui P, Huttner A, Fulbright R, Baehring J

8:10pm Investigation of N-acetylcysteine for the NTOX-04 prevention of cisplatin chemotherapy-related cognitive impairments Lomeli N, Di K, Czerniawski J, Guzowski J, Bota D

8:14pm Prognostic factors and outcomes of patients CMET-08 with central nervous system (CNS) metastatic ALK-rearranged non-small cell lung cancer (NSCLC) Kachur E, Reiss S, Land J, Buie L, Reiner A, Panageas K, Riely G, Pentsova E

8:18pm Survival outcomes in pediatric recurrent high-PDCT-17 grade glioma: results of a 20-year systematic and meta-analysis Kline-Nunnally C, Felton E, Allen E, Tahir P, Mueller S

8:22pm Hispanic ethnicity and socioeconomic status EPID-14 are independently associated with improved prognosis in glioblastoma patients Ivan M, Richardson A, Moore K, Omuro A, De La Fuente M, Koru-Sengul T

8:26pm HER2 and triple negative breast cancer CMET-44 patients demonstrate an earlier time to development of brain metastases Cao T, Santa-Maria C, Kumthekar P




Imaging/Pediatrics/Outcomes/Practical and Applied Neuro-Oncology/PathologyModerators: Jason Huse, Cynthia Wetmore

M A I N M E E T I N G P R O G R A MSaturday, November 18, 2017



Novel Metabolic Targets and Their Genetic Basis in GliomaDaniel Cahill (Chair)

• Metabolic profiling of gliomaSabrina Ronen

• Temozolomide and metabolism in IDH1 mutant gliomaDaniel Cahill

• Lipogenesis and glioblastomaDeliang Guo

• Metabolic dependencies induced by IDH1 mutationSamuel McBrayer

EANO/SNO: Glioblastoma in the Elderly: Solid Conclusions Build on Shifting Sand?Wolfgang Wick, Tracy Batchelor (Co-Chairs)

• Specific requirements of elderly patientsRoberta Rudá

• Update on molecular biomarkers in the elderlyJason Huse

• Surgery in the elderly glioma patientColin Watts

• Standard of care postsurgical therapy 2017James Perry

Using Patient Reports as a Measure of Net Clinical BenefitChristina Amidei (Chair)

• Integrating patient report measures into neuro-oncology clinical practice: Opportunities for targeted interventionsChristina Amidei

• Understanding the natural history of rare CNS tumors through patient self-report and web-based portalsTerri Armstrong

• Applying patient report measures as quality metrics in pediatric brain tumor careJin Shei Lai

• Innovative patient report measures in researchMartin Taphoorn

Histone Mutations in Pediatric GliomasCynthia Hawkins (Chair)

• Oncohistones: Professional hijackers of the epigenomeNada Jabado

• The ABCs of chromatin biology and biochemical insights into the mechanisms of histone mutationsPeter Lewis

• Diagnostic and prognostic implications of histone mutations in clinical practiceCynthia Hawkins

• Targeting histone mutations in the clinic, are we there yet?Oren Becher

Brain MetastasesAdrienne Boire (Chair)

• Microenvironmental interactions in brain metastasisAdrienne Boire

• Brain metastasis genomicsPriscilla Brastianso

• Targeted therapy in brain metastasisManmeet Ahluwalia

• Brain metastasis-microenvironment interactions: an emerging source of innovative therapiesManuel Valiente

Tumor Related EpilepsyJeffrey Politsky (Chair)

• EEG monitoring and brain mapping in TREJeffrey Politsky

• Epidemiology and etiology of TREJoon Uhm

• Medical/pharmacologic considerations in TREPatrick Wen

• Surgical management of tumor-related epilepsySandeep Mittal

12:15-1:15pm LUNCH

LUNCHTIME TUTORIALS AND EDUCATIONAL SESSIONSNot sponsored by The University of Texas MD Anderson Cancer Center

Introduction to CRISPR-based TechnologiesDaniel Lim (Chair)• CRISPRi and CRISPRa for programmable transcriptional control, Daniel Lim• Opportunities and challenges of CRISPR-Cas gene editing, Jennifer Doudna• CRISPR/Cas9 for genome editing, Alexander Marson

Basic Science in Neuro-oncology for the ClinicianVinay Puduvalli (Chair)• Biology of primary brain tumors – the basics, Vinay Puduvalli• Basic immunology for the clinician, Amy Heimberger• Genomics and epigenomics in neuro-oncology: making sense of the maze, Russell Pieper

Quantitative Biology in Neuro-oncologyAntonio Iavarone (Chair)• Public portal pearls and pitfalls; a hitchhiker’s guide to available data and analysis resources, Cameron Brennan• Large scale systems biology in brain cancer genomics, Michele Ceccarelli• Functional characterization of glioma cancer genes, Antonio Iavarone

Young Investigators Lunch - Demystifying the Grant Application Process• Pre-grant preparation, Balveen Kaur• Writing the grant, Eva Galanis• Addressing an unfunded grant, Justin Lathia• The NIH perspective, Jane Fountain


9:00-12:00pm SATURDAY PLENARY SESSION

9:00-9:05am Welcome and Introduction Manish Aghi, Frank Furnari, Vinay Puduvalli

9:05-9:35am Keynote Presentation: New cancer technologies Jennifer Doudna

9:35-10:05am Keynote Presentation: MicroRNA dysregulation to identify therapeutic targets Carlo Croce

10:05-10:35am Victor Levin Award Introduction: Victor Levin

Victor Levin Lecture - Award Recipient: Susan Chang

10:35-10:50am BREAK

10:50-11:20am Presidential Address: E. Antonio Chiocca

11:20-11:25am Lifetime Achievement Award Recipient: Webster Cavenee

11:25-11:30am Platinum Supporter Awards

11:30-12:00pm LATE BREAKING ABSTRACTS

11:30-11:45am Results of the randomized phase II study on ABT414 alone, ABT414 in combination with temozolomide and either LTBK-04 temozolomide or lomustine in recurrent EGFR amplified glioblastoma: a report from INTELLANCE 2/EORTC trial 1410 van den Bent M, Eoli M, Sepulveda J, Smits M, Walenkamp A, Frenel J, Brandes A, Clement P, French P, Dubbink H, Kros J, Weller M, Chinot O, de Vos F, Whenham N, Sanghera P, Looman J, Lee H, de Geus J, Nuyens S, Spruyt M, Brilhante J, Gorlia T, Golfinopoulos V

11:45-12:00pm Multicenter randomized placebo-controlled trial of autologous formalin-fixed tumor vaccine for newly-diagnosed LTBK-03 glioblastomas Muragaki Y, Maruyama T, Ishikawa E, Nitta M, Ikuta S, Tsuboi K, Matsumura A, Nakamura H, Abe T, Saito R, Tabei Y, Arakawa Y, Momii Y, Karasawa K, Matsutani M, Ohno T, Nakazato Y, Maebayashi K


12:15-1:15pm LUNCH, continued

Surgical Trials: From Design to Regulatory ApprovalConstantinos Hadjipanayis (Chair)• Clinical trial design for neurosurgeons, Michael Vogelbaum• Getting FDA approval for devices and diagnostic tools (5-ALA), Constantinos Hadjipanayis• Phase 0 clinical trials and associated opportunities for neurosurgeons, Nader Sanai

Industry Supported SymposiaNot sponsored by The University of Texas MD Anderson Cancer Center • EGFR targeted therapy for leptomeningeal carcinomatosis in non-small cell lung cancer: A prIME satellite

symposium held in conjunction with the 22nd Annual Meeting for the Society of Neuro-Oncology• EGFR targeted therapy in GBM


CONCURRENT SESSION 5AMetabolomics/Cell Biology/Cell SignalingModerators: Zhimin Lu, Daniel Cahill

1:30-1:40pm Hypoxia inducible factor 1α reprograms METB-11 choline and ethanolamine phospholipid metabolism in mutant IDH1 gliomas Viswanath P, Phillips J, Pieper R, Ronen S

1:40-1:50pm Identification of a sexual dimorphism in METB-05 glioma pyruvate metabolism Wang Z, Rubin J, Ippolito J

1:50-1:55pm Targeting metabolic adaptation in MYC PDTM-46 driven pediatric neuronal tumors Delaidelli A, Negri G, Jan A, Jansonius B, Lim J, Leprivier G, Kool M, Pfister S, Remke M, Taylor M, Maris J, Sorensen P

1:55-2:00pm EGFR and EGFRvIII upregulate macrophage TMIC-51 infiltration in glioblastoma through TLR2 An Z, Weiss W

2:00-2:05pm Hyperpolarized [1-13C] pyruvate as a EXTH-71 biomarker for treatment monitoring in lymphoma murine models Tiret B, Autry A, Park I, Lu M, Anjum R, Drew L, Degorce S, Mayo M, Dillman K, Rubenstein J, Chaumeil M

2:05-2:15pm Reversal of glioblastoma replicative CSIG-38 immortality in a TERT promoter mutation- dependent manner Mancini A, Xavier-Magalhaes A, Woods W, Nguyen K, Amen A, McKinney A, Hayes J, Song J, Costa B, Perez-Pinera P, Costello J

2:15-2:25pm Clonal dynamics of human glioblastoma in TMOD-06 response to chemoradiotherapy Qazi M, Nixon A, Bakhshinyan D, Venugopal C, Vora P, Brown K, Subapanditha M, Yelle N, Chokshi C, Seyfrid M, Moffat J, Singh S

2:25-2:35pm Directed neuronal differentiation in GBM by CBIO-08 suppression of TAZ Audia A, Das A, Mukheef F, Zhang Z, Sulman E, Bhat K

2:35-2:45pm CIC protein instability drives cancer CSIG-23 phenotypes in glioblastoma Bunda S, Heir P, Metcalf J, Pusch S, Zadeh G, Aldape K

2:45-2:50pm ACOT7 regulates colonization of breast CBIO-29 cancer cells in the brain by regulating endoplasmic reticulum stress response Kanojia D, Panek W, Cordero A, Xiao A, Miska J, Wu M, Kim J, Zhou W, Ahmed A, Lesniak M

2:50-2:55pm Regulation of glioblastoma bioenergetics by CSIG-25 AMP kinase Dasgupta B, Chhipa R

2:55-3:00pm Induction of autophagy following TTFields CBIO-16 application serves as a survival mechanism mediated by AMPK activation Shteingauz A, Porat Y, Giladi M, Schneiderman R, Voloshin T, Munster M, Kirson E, Weinberg U, Palti Y

3:00-3:05pm Patient-derived glioblastoma cells release CBIO-22 ciliary vesicles that stimulate tumor cell proliferation Hoang-Minh L, Breunig J, Sarkisian M

3:05-3:10pm Pre-clinical study and clinical development of CSIG-31 AXL-targeting therapy for recurrent glioblastoma Sadahiro H, Kang K, Nabors B, Norian L, Hambardzumyan D, Dasgupta B, Nakada M, Nakano I



CONCURRENT SESSION 5BPractical and Applied Neuro-Oncology IModerators: Terri Armstrong, Martin Taphoorn

1:30-1:35pm Introduction Susan Chang

1:35-1:50pm Neurocognitive functioning in EORTC Brain NCOG-08 Tumor Group randomized phase II TAVAREC trial (EORTC 26091, NCT01164189) on temozolomide with or without bevacizumab in 1p/19q intact recurrent grade II and III gliomas Klein M, Reijneveld J, Idbaih A, Taal W, Clement P, de Vos F, Wick A, Mulholland P, Taphoorn M, Lewis J, Weller M, Verschuere T, Golfinopoulos V, Gorlia T, van den Bent M

1:50-2:05pm Cognitive functions and variants in genes NCOG-11 associated with aging and inflammation in brain tumor patients Correa D, Satagopan J, Onyewadume L, Kryza-Lacombe M, Leong S, Dimitriadoy S, O’Connell K, DeAngelis L, Orlow I

2:05-2:15pm Memory functioning in low-grade glioma NCOG-07 patients treated with either radiotherapy (RT) or temozolomide (TMZ) chemotherapy. A correlative analysis of European Organization for Research and Treatment (EORTC) study 22033-26033 Klein M, Drijver J, van den Bent M, Hoang-Xuan K, Taphoorn M, Reijneveld J, Hassel M, Eekers D, Tzuk T, Lucas A, Golfinopoulos V, Gorlia T, Stupp R, Baumert B

2:15-2:25pm The added value of Health-Related Quality QLIF-27 of Life (HRQoL) as a prognostic indicator of overall survival and progression free survival in glioma patients: a meta-analysis based on individual patient data from randomized controlled trials Coomans M, Dirven L, Aaronson N, Baumert B, van den Bent M, Bottomley A, Brandes A, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Wick W, Reijneveld J, Taphoorn M

2:25-2:35pm Risk of glioma among people with asthma: EPID-19 a population-based case-control study using different control groups Lachance D, Kaur H, Ryan C, Sheen Y, Seol H, Wi C, King K, Ryu E, Juhn Y

2:35-2:45pm Neurocognitive outcomes of EORTC Brain NCOG-19 Tumor Group study 26101 phase III trial comparing the combination of lomustine and bevacizumab with lomustine alone in glioblastoma patients with first progression Klein M, Reijneveld J, Idbaih A, Brandes A, Taal W, Clement P, Domont J, Campone M, Taphoorn M, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, Golfinopoulos V, Platten M, Gorlia T, van den Bent M, Wick W

2:45-2:55pm Health related quality of life and QLIF-47 neurological deterioration free survival in INTELLANCE 2/EORTC trial 1410, a randomized phase II study on ABT414 in recurrent EGFR amplified glioblastoma Clement P, van den Bent M, Eoli M, Sepulveda J, Walenkamp A, Frenel J, Franceschi E, Weller M, Chinot O, de Vos F, Whenham N, Sanghera P, Looman J, Lee H, de Geus J, Nuyens S, Spruyt M, Gorlia T, Coens C, Golfinopoulos V

2:55-3:05pm Burnout among neuro-oncology professionalsQLIF-39 Yust-Katz S, O’Brien B, Acquaye A, Vera E, Armstrong T

3:05-3:15pm Risk factors for burnout among neuro-QLIF-30 oncology providers: a predictive model O’Brien B, Yust-Katz S, Vera E, Acquaye A, Armstrong T

3:15-3:30pm BREAK

CONCURRENT SESSION 5CImagingModerators: Sabrina Ronen, Joerg-Christian Tonn

1:30-1:40pm Photopenic defects on O-(2-18F-fluoroethyl)-NIMG-47 L-tyrosine PET - clinical relevance in glioma patients Galldiks N, Unterrainer M, Judov N, Stoffels G, Lohmann P, Vettermann F, Dunkl V, Suchorska B, Tonn J, Kreth F, Fink G, Bartenstein P, Langen K, Albert N

1:40-1:50pm Experience with 18F-FET PET/MRI for CNS-NIMG-42 tumors in children and adolescents Marner L, Nysom K, Sehested A, Borgwardt L, Mathiasen R, Wehner P, Henriksen O, Lundemann M, Thomsen C, Bøgeskov L, Skjøth-Rasmussen J, Broholm H, Scheie D, Juhler M, Højgaard L, Law I

1:50-1:55PM Usefulness of 18FET-PET for chemotherapy NIMG-100 monitoring in non-contrast enhancing glioma Suchorska B, Unterrainer M, Biczok A, Albert N, Tonn J, Kreth F

1:55-2:00pm Patterns of intersectional tumour volume NIMG-39 in T2-weighted MRI and 18F-FET PET correlate with outcome in glioblastoma Suchorska B, Sosnova M, Unterrainer M, Biczok A, Bartenstein P, Albert N, Tonn J

2:00-2:10pm Radiomic analysis of pseudo-progression NIMG-91 compared to true progression in glioblastoma patients: A large-scale multi- institutional study Abrol S, Kotrotsou A, Hassan A, Elshafeey N, Agarwal A, Hassan I, Idris T, Salek K, Farid N, McDonald C, Weathers S, Bahrami N, Bergamaschi S, Elakkad A, Alfaro-Munoz K, Moron F, Huse J, Weinberg J, Heimberger A, Sawaya R, Kumar A, de Groot J, Law M, Zinn P, Colen R

APPLIED NEURO-ONCOLOGY AWARD

APPLIED NEURO-ONCOLOGY AWARD


2:10-2:20pm Rapid accurate intraoperative diagnosis of NIMG-22 pediatric brain tumors using stimulated Raman histology Hollon T, Lewis S, Pandian B, Niknafs Y, Garton H, Maher C, Muraszko K, Camelo-Piragua S, Orringer D

2:20-2:30pm Impact of post-surgical enhancing tumor NIMG-77 volume and T2/FLAIR volume on the survival impact of bevacizumab in NRG Oncology/ RTOG 0825 Vogelbaum M, Swanson K, Zhang P, Cahill D, Hawkins-Daarud A, Gilbert M, De Leon G, Rickertsen C, Kunkel L, Shi W, Penas-Prado M, Youssef E, Shu H, Wendland M, Suh J, Keech J, Howard S, Kaluza V, Won M, Mehta M

2:30-2:40pm Resting state functional MRI shows NIMG-95 disturbances in functional connectivity in the non-lesional hemisphere in patients with high-grade glioma Stöcklein V, Stoecklein S, Ertl-Wagner B, Thon N, Kreth F, Tonn J, Liu H

2:40-2:50pm Deep learning approaches to identify intra-NIMG-89 tumoral heterogeneity of low and high grade gliomas Chang P, Bota D, Filippi C, Chow D

2:50-2:55pm P53 amplification modifies the glioblastoma NIMG-99 microenvironment: Differentiating the contribution of cells vs edema in the T2 weighted MRI signal Jackson P, Gaw N, Hawkins-Daarud A, DeGirolamo L, Baxter L, Smith K, Nakaji P, McGee S, Clark- Swanson K, Bendok B, Wu T, Hu L, Li J, Swanson K

2:55-3:00pm Shape attributes of enhancing lesion NIMG-80 boundaries can differentiate tumor recurrence from pseudo-progression on routine brain MRI scans: Preliminary findings Isamail M, Prasanna P, Huang R, Singh G, Thawani R, Madabhushi A, Ahluwalia M, Tiwari P

3:00-3:05pm Deep learning for survival predicting in IDH NIMG-96 wild-type gliomas Chang P, Chow D, Bota D, Poisson L, Filippi C, Jain R

3:05-3:10pm Increased mutation burden (hypermutation) NIMG-28 in gliomas is associated with a unique radiomic texture signature in magnetic resonance imaging Hassan I, Kotrotsou A, Kamiya Matsuoka C, Alfaro-Munoz K, Elshafeey N, Zinn P, de Groot J, Colen R


3:15-3:30pm BREAK

CONCURRENT SESSION 6ACNS MetastasesModerators: Manmeet Ahluwalia, Priscilla Brastianos

3:30-3:40pm Introduction Paul Brown

3:40-3:55pm High aldehyde dehydrogenase activity TMIC-07 identifies brain metastasis-initiating cells in breast cancer Minata M, Alsheikh H, Harada S, Peker D, Gillespie Y, Cerione R, Tannous B, Nakano I, Samant R, Lu S, Yamaguchi S

3:55-4:05pm Identification of a novel tyrosine kinase/ ANGI-12 integrin complex that drives brain metastases Jahangiri A, Sidorov M, Nguyen A, Yagnik G, Han S, Mascharak S, De Lay M, Wagner J, Castro B, Imber B, Lu K, Bergers G, Weiss W, Aghi M

4:05-4:15pm PIK3 mutations are associated with RTHP-33 decreased local control in brain metastases treated with radiation Lockney N, Wang D, Lin A, Pei X, Chan T, Yamada Y, Beal K, Yang T

4:15-4:25pm Pan-cancer profiles of brain metastases: CMET-09 prioritization of therapeutic targets Ferguson S, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos P, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, Zhang J, Ibrahim N, de Groot J, McCarty J, O’Brien B, Sawaya R, Verhaak R, Reddy S, Priebe W, Spetzler D, Heimberger A

4:25-4:30pm Detection, molecular profiling and culture of CMET-36 CSF-CTCs in leptomeningeal disease (LMDz) in melanoma Evernden B, Law V, Kenchappa R, Puskas J, Ryzhova E, Fedorenko I, Tran N, Etame A, Sahebjam S, Magliocco A, Smalley K, Forsyth P

4:30-4:35pm T lymphocytes facilitate brain metastasis of IMMU-56 breast cancer by expressional imprinting Pedrosa R, Valiente M, Luider T, Debets R, Kros J, Mustafa D

4:35-4:40pm N107C/CEC.3 (Alliance for Clinical Trials NCOG-06 in Oncology/Canadian Cancer Trials Group): Phase III Trial of post-operative radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease: cognitive function of long-term survivors Roberge D, Ballman K, Cerhan J, Anderson S, Carrero X, Whitton A, Greenspoon J, Parney I, Laack N, Ashman J, Bahary J, Hadjipanayis C, Urbanic J, Barker F, Farace E, Khuntia D, Garces Y, Giannini C, Buckner J, Galanis E, Brown P


4:40-4:45pm Pretreatment volume of MRI-determined NCOG-02 white matter injury (WMI) predicts cognitive decline after hippocampal avoidant (HA) WBRT for brain metastases: Secondary analysis of NRG Oncology RTOG 0933 Bovi J, Pugh S, Sabsevitz D, Robinson C, Paulson E, Mehta M, Gondi V, Kundapur V, Pinover W, Chao S, Machtay M, DeNittis A, Laack N, Greenspoon J, Mannel R, Huang J, Dominello M, Kachnic L

4:45-4:50pm Impact of tumor size and molecular profile CMET-11 on local control in patients with breast cancer brain metastases: understanding tumor biology and radiosurgery dosing Kotecha R, Miller J, Mohammadi A, Murphy E, Suh J, Barnett G, Vogelbaum M, Angelov L, Ahluwalia M, Chao S

4:50-4:55pm Overall survival of melanoma brain CMET-41 metastasis patient cohorts treated with stereotactic radiosurgery with or without immunotherapy Nguyen S, Pearson L, Keller A, All S, Patel H, Ramakrishna N


CONCURRENT SESSION 6BPractical and Applied Neuro-Oncology IIModerators: Zarnie Lwin, Jeffrey Wefel

3:30-3:40pm Illness communication, spousal support and QLIF-10 symptom burden in couples coping with Glioma Milbury K, Lopez G, Weathers S, Eto O, Li J, Cohen L

3:40-3:50pm Genetic markers and clinical characteristics NCOG-20 related to neurocognitive outcomes of pediatric brain tumor patients Kline-Nunnally C, Felton E, Edwards C, Fullerton H, Torkildson J, Gauvain K, Samuel D, Mueller S

3:50-4:00pm Health-related quality of life results from QLIF-12 the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact firs recurrence WHO grade II and III glioma (EORTC 26091) Reijneveld J, Coens C, Taphoorn M, Sillevis Smitt P, Clement P, Idbaih A, de Vos F, Klein M, Wick W, Mulholland P, Lewis J, Golfinopoulos V, Bottomley A, van den Bent M

4:00-4:05pm Hospice use among patients with high grade PALL-08 gliomas Forst D, Adams E, Nipp R, Martin A, Aizer A, Jordan J

4:05-4:10pm A pilot study of cognitive functions, APOE NCOG-16 and amyloid imaging in glioma patients Correa D, Kryza-Lacombe M, Zhou X, Baser R, Beattie B, Beiene Z, Humm J, DeAngelis L, Orlow I, Weber W, Osborne J

4:10-4:15pm Psychological distress and prognostic PALL-09 understanding in patients with malignant gliomas and their caregivers Forst D, Quain K, Poisson K, Eusebio J, Jackson V, Greer J, El-Jawahri A, Temel J

4:15-4:20pm Effects of integrative therapies on distress, QLIF-35 pain, and fatigue in patients with primary brain tumors: preliminary results from an integrative medicine registry Donovan L, Rusilowski A, Taromina K, Kreisl T, Welch M, Lassman A, Ladas E, Iwamoto F

4:20-4:25pm I-CoPE: A pilot study of an innovative model PALL-03 of supportive and palliative care for patients with high grade glioma and their family carers Philip J, Collins A

4:25-4:30pm Seizure control after initial presentation in NCMP-01 IDH mutated glioma patients Ozer B, Bui Y, Markovic D, Nguyen H, Liau L, Nghiemphu P, Cloughesy T, Lai A

4:30-4:35pm Design and implementation of a survivorship QLIF-06 programme in an unselected cohort of newly diagnosed brain tumour patients: feasibility and application of routine holistic needs assessment McBain C, Emerson J, Molloy E, Robson S, Cundliffe S, Gilston-Hope A, Smith C, Wadeson A

4:35-4:40pm Postoperative delirium in glioblastoma NTOX-10 patients: Risk factors and prognostic implications Flanigan P, Jahangiri A, Weinstein D, Kanungo I, Choi S, Dayani F, Molinaro A, McDermott M, Berger M, Aghi M

4:40-4:45pm Improved survival of glioblastoma patients HOUT-12 treated at academic cancer programs: A Hospital-based Study from the National Cancer Database Zhu P, Du X, Zhu J, Esquenazi Y

4:45-4:50pm Neuro-oncology burnout: impact of QLIF-02 professional stressors and job satisfaction Acquaye A, Vera E, Yust-Katz S, O’Brien B, Armstrong T



CONCURRENT SESSION 6CRANO UpdateModerators: Susan Chang, David MacDonald, Martin van den Bent, Michael Vogelbaum, Patrick Wen

3:30-3:35pm Introduction Patrick Wen

3:35-3:50pm Brain metastases clinical trial design and endpoints Eudocia Quant Lee, Brian Alexander

3:50-3:55pm Leptomeningeal disease Riccardo Soffietti, Manmeet Ahluwalia

3:55-4:05pm PET Joerg-Christian Tonn

4:05-4:11pm Meningioma Patrick Wen, Ray Huang, Michael Vogelbaum

4:11-4:18pm NANO Lakshmi Nayak, David Reardon

4:18-4:28pm Seizures-the next step; redesign outcome measures Edward Avila

4:28-4:38pm Patient reported outcomes Martin Taphoorn, Terri Armstrong

4:38-4:45pm Steroids Patrick Wen, Nils Arvold

4:45-4:55pm Proposal for new baseline MRI for newly diagnosed HGG effort Benjamin Ellingson

4:55-5:03pm Novel endpoints for low grade gliomas Raymond Huang

5:03-5:11pm Challenges in assessing response to therapy in recurrent patients in the postoperative setting Peter Canoll

5:11-5:21pm Phase 0 trials in Neuro-Oncology Michael Vogelbaum

5:21-5:30pm Next steps Patrick Wen

5:00-7:00pm POSTER SESSION Traditional Poster Viewing5:30-7:30pm EVENING SURVIVORSHIP SESSION Identifying Needs and Developing Interventions7:15-11:00pm SNO GALA Held at AT&T Park, home of the San Francisco Giants baseball team (Separate Ticket Required)

5:00-7:00pm E-TALKS Interactive Electronic 4 Minute Presentations Followed By Group Discussions Group 1: Adult Therapeutics Group 2: Angiogenesis/Invasion/Microenvironment/Immunology Group 3: Pediatric Basic Science/Stem Cells



Adult TherapeuticsModerators: Jian Campian, Michelle Kim

5:28pm Phase I trial of anti-LAG-3 or anti-CD137 ATIM-23 alone and in combination with anti-PD-1 in patients with recurrent GBM Lim M, Ye X, Nabors B, Piotrowski, MD A, Fisher J, Desideri S, Sims M, Wen P, Grossman S

5:32pm A Phase 1 study of Ad-RTS-hIL-12 + ATIM-26 veledimex in adult recurrent glioblastoma Chiocca E, Yu J, Lukas R, Buck J, Demars N, Barrett J, Yang Y, Cooper L, Lebel F

5:36pm Recommended phase II dose of intra-arterial NTOX-09 melphalan given with intra-arterial carboplatin, osmotic blood-brain barrier disruption and delayed otoprotective sodium thiosulfate for patients with recurrent or progressive CNS embryonal or germ cell tumors Ambady P, Doolittle N, Firkins J, Prola Netto J, Siler D, James J, Johansson K, Huddleston A, Fu R, Neuwelt E

5:40pm Post-surgical, residual enhancing tumor NIMG-53 volume is prognostic for overall survival in newly diagnosed glioblastoma: Evidence from 1,458 patients pooled from international trials, single institution databases, and multicenter consortiums Ellingson B, Abrey L, Nelson S, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason W, Wick W, Butowski N, Ligon K, Gerstner E, Colman H, de Groot J, Chang S, Mellinghoff I, Young R, Colen R, Taylor J, Arrillaga-Romany I, Huang R, Pope W, Reardon D, Batchelor T, Wen P, Prados M, Cloughesy T

5:44pm Radiation therapy patterns of care for CMET-13 non-small cell lung cancer brain metastases: an analysis of the National Cancer Database Dulaney C, Fiveash J, Li P, Boggs H

5:48pm Survival benefit associated with adjuvant MNGI-10 radiotherapy in elderly patients with WHO grade III meningioma Zhou H, Huang R, Karakousis G, Zhang P, Chan L, Bai H, Xiao B, Yang L

5:52pm The effect of immunotherapy treatment CMET-32 on local control for melanoma brain metastases treated with stereotactic radiosurgery Pearson L, Nguyen S, Keller A, All S, Patel H, Ramakrishna N

5:56pm Efficacy and toxicity of stereotactic CMET-24 radiosurgery for treatment of patients with 10 or more brain metastases Braunstein S, Garcia M, Scharfen J, Ma L, Nakamura J, Fogh S, Aghi M, Theodosopoulos P, McDermott M, Sneed P

5:00pm A phase Ib/II, open-label, multicenter study of ACTR-74 capmatinib (INC280) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma van den Bent M, Azaro A, Vos F, Sepulveda J, Yung W, Wen P, Lassman A, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Vicente S, Myers A, Wick W

5:04pm The efficacy of ketogenic diet with ACTR-12 concomitant intranasal perillyl alcohol as a novel strategy for therapy of recurrent glioblastoma Fonseca C, Santos J

5:08pm A phase I study of neural stem cells loaded ACTR-36 with an oncolytic adenovirus for patients with newly diagnosed malignant glioma: Preliminary safety and data analysis Lesniak M, Stupp R, Sachev S, Lukas R, Chandler J, Portnow J, Amidei C, Miska J, Balyasnikova I, Ahmed A, Curiel D, Strong T, LeFever A, Adams A, Giles F, Aboody K

5:12pm Phase I trial of TG02 plus dose-dense or ACTR-69 metronomic temozolomide for adults with recurrent anaplastic astrocytoma and glioblastoma Wu J, Bryla C, McCoy A, Lisa B, Garren N, Siegel C, Grajkowska E, Theeler B, Park D, Parrott T, Armstrong T, Yuan Y, Gilbert M

5:16pm Comparison of local control of brain CMET-43 metastases with stereotactic radiosurgery versus surgical resection: A secondary analysis of EORTC 22952-26001 Churilla T, Chowdhury I, Handorf E, Collette L, Collette S, Dong Y, Alexander B, Kocher M, Soffietti R, Claus E, Weiss S

5:20pm Final analysis of phase II combining MNGI-13 everolimus and octreotide for patients with refractory and documented progressive meningioma (CEVOREM) Graillon T, Sanson M, Peyre M, Peyrière H, Autran D, Kalamarides M, Roche P, Fuentes S, Tabouret E, Barrie M, Campello C, Idbaih A, Boucekine M, Figarella-Branger D, Barlier A, Dufour H, Chinot O

5:24pm A 2-part safety and exploratory efficacy ACTR-56 randomised double-blind, placebo- controlled study of a 1:1 ratio of cannabidiol and delta9tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM) Short S, Little C, The Cannabinoid in Recurrent Glioma Study Group

5:00pm Inhibition of APLN-APLNR signalling blocks ANGI-02 tumour angiogenesis and attenuates invasive glioblastoma growth Glass R, Mastrella G, Hou M, Stöcklein V, Miletic H, Herold-Mende C, Synowitz M, Vescovi A, Bjerkvig R, Schüller U, Tonn J, Kaelin R

5:04pm Accurate patient-specific machine learning NIMG-68 models of glioblastoma invasion using transfer learning Hu L, Yoon H, Eschbacher J, Baxter L, Smith K, Nakaji P, Mcgee S, Dueck A, Quarles C, Karis J, Hawkins-Daarud A, Jackson P, Massey S, Wu T, Swanson K, Li J

5:08pm Radiomics of tumor invasion 2.0: combining NIMG-74 mechanistic tumor invasion models with machine learning models to accurately predict tumor invasion in human glioblastoma patients Swanson K, Gaw N, Hawkins-Daarud A, Jackson P, Singleton K, DeGirolamo L, Eschbacher J, Baxter L, Smith K, Nakaji P, McGee S, Clark-Swanson K, Bendok B, Dueck A, Wu T, Li J, Hu L

5:12pm Regulation of the protease ADAM17 by TMIC-48 extracellular signals drives pro-tumoral programs in glioblastoma cells and their microenvironment Nandhu M, Bhaskaran V, Hu B, Viapiano M

5:16pm Quantifying interstitial fluid flow in TMIC-28 glioblastoma using dynamic contrast enhanced MRI Kingsmore K, Munson J

5:20pm Deciphering glioma intrinsic transcriptional TMIC-22 subtypes identifies tumor evolution associates with changes in immune- microenvironment Wang Q, Hu B, Hu X, Squatrito M, Scarpace L, deCarvalho A, Lyu S, Li P, Li Y, Barthel F, Cho H, Lin Y, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Olar A, Lan Z, Finocchiaro G, Phillips J, Berger M, Gabrusiewicz K, Wang G, Eskilsson E, Hu J, Mikkelsen T, Depinho R, Muller F, Heimberger A, Sulman E, Nam D, Verhaak R

5:24pm Inhibition of SLC7A11 reduces excitatory TMIC-20 synaptic input of peritumoral neurons in glioma patients Sauvigny T, Dührsen L, Kuhl D, Westphal M, Ohana O, Martens T

5:28pm A novel chimeric model to accurately IMMU-50 identify TAMMs in glioblastoma Youshani A, Yu K, Wilkinson F, O’Leary C, Cook P, Liao A, Pathmanaban O, Waugh C, Shorrock H, MacDonald A, Roncaroli F, Kamaly-Asl I, Bigger B

5:32pm Reducing the ex vivo manufacturing time IMMU-17 of EGFRvIII-specific chimeric antigen receptor (CAR) T cells improves phenotype and demonstrates potent anti-glioma function in vivo Tanaka R, Caruso H, Ling X, Najjar A, Heimberger A

5:36pm Overcoming glioblastoma resistance to IMMU-63 immune checkpoint blockade via RNA- loaded nanoparticles Sayour E, Grippin A, Mendez-Gomez H, De Leon G, Mitchell D

5:40pm Immunological activation in responding ATIM-25 patients with recurrent HGG after treatment with Toca 511 & Toca FC: Results from a phase 1 trial Ostertag D, Accomando W, Hogan D, Diago O, Gammon D, Haghighi A, Mitchell L, Rodriguez- Aquirre M, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Chen C, Vogelbaum M, Gruber H, Das A, Jolly D

5:44pm Tumor genetics and macrophage ontogeny TMIC-11 shape the innate immune response to glioma Mueller S, Kohanbash G, Liu S, Carrera D, Watchmaker P, Jahan N, Alvarado B, Lim D, Aghi M, Okada H, Diaz A

5:48pm CD317 expression in human glioblastoma: a IMMU-54 target for immunotherapy Gramatzki D, Szabo E, Gramatzki M, Peipp M, Weller M

5:52pm GCN2 kinase is essential for adaptive T-cell IMMU-06 immunity in glioma Rashidi A, Miska J, Pituch K, Kanojia D, Lopez- Rosas A, Han Y, Kim J, Panek W, Muroski M, Lesniak M

5:56pm A liquid biopsy to assess tumor recurrence: EXTH-63 presence of Mo-MDSC and CD14+ VNN2+ cells in peripheral blood as a biomarker to distinguish brain metastasis (BM) from radiation necrosis after stereotactic radiosurgery Soler D, Young A, Kerstetter-Fogle A, Barnholtz- Sloan J, Cooper K, McCormick T, Sloan A



Angiogenesis/Invasion/Microenvironment/ImmunologyModerators: Katrin Lamszus, Jing Wu

Pediatric Basic Science/Stem CellsModerators: Vivianne Tabar, Sameer Agnihotri

5:00pm Characterization of the senescence-PDTM-47 associated secretory phenotype in pilocytic astrocytoma and its role in oncogene- induced senescence Hohloch J, Selt F, Hielscher T, Sahm F, Capper D, Usta D, Ecker J, Oehme I, van Tilburg C, von Deimling A, Schuhmann M, Korshunov A, Jones D, Brummer T, Pfister S, Witt O, Milde T

5:04pm Systematic drug identifies Digoxin as a PDTM-07 drug that prolongs survival in PDOX models of groups 3 and 4 medulloblastoma at clinically relevant doses Injac S, Huang L, Zhao H, Qi L, Kogiso M, Man C, Li X-N, Lau, C, Wong S

5:08pm Radiation DNA damage repair inhibition by PDTM-44 GSK-J4 induced chromatin compaction in DIPG Louis N, He X, Piunti A, Morgan M, Unruh D, Saratsis A, Lulla R, Fangusaro J, Horbinski C, Goldman S, James C, Shilatifard A, Hashizume R

5:12pm Next-generation sequencing of diffuse PDTM-02 intrinsic pontine glioma cells reveals altered epigenetic regulation and distinct tumor subgroups Saratsis A, Huang T, Bartom E, Marshall S, Qi J, Hashizume R, James C, Shilatifard A

5:16pm Regulation of bioenergetics through dual METB-15 inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres Park J, Shim J, Kang J, Kim E, Chang J, Kim S, Kang S

5:20pm Functional genomic analysis of MYC-PDTM-36 amplified medulloblastoma nominates the TGFb pathway as a clinically viable target Henderson J, Cho H, Davare M, Tsherniak A, Cowley G, Weir B, Hahn W, Cho Y

5:24pm Effective preclinical treatment of diffuse PDTM-42 intrinsic pontine glioma by MELK inhibition Meel M, Guillén-Navarro M, de Gooijer M, Waranecki P, Buil L, Koster J, Montero Carcaboso A, van Vuurden D, van Tellingen O, Kaspers G, Hulleman E

5:28pm Toca 511 & Toca FC: Pre-clinical proof of PDTM-19 concept in medulloblastoma Richardson A, Collins S, Inagaki A, Armstrong V, Roussel M, Jolly D, Robbins D, Ayad N, Kasahara N

5:32pm Modeling glioblastoma through cancer stem TMOD-16 cell organoids Hubert C, Rivera M, Wallace L, Wu Q, Mack S, Prager B, Miller T, Couce M, McLendon R, Sloan A, Rich J

5:36pm Human stem cell based model of TMOD-11 medulloblastoma Huang M, Tailor J, Zhen Q, Phillips J, Morrissy S, Kool M, Pfister S, Swartling F, Taylor M, Smith A, Weiss W

5:40pm Lamina organization promotes maintenance STEM-29 of brain tumor initiating cells in glioma Lai S, Prager B, Wang X, Rich J

5:44pm The TCF12 transcription factor controls STEM-19 proneural glioblastoma stem-like cells Taiwo R, Mao D, Mahlokozera T, Kim A

5:48pm DOT1L epigenetically regulates GBM brain STEM-28 tumor stem cells Bozek D, Wang A, Hao X, Johnston M, Luchman H, Weiss S

5:52pm High expression of LGR5 maintains CBIO-25 glioblastoma stem cells in a proneural state and promotes self-renewal and invasion Xie Y, Sundström A, Tan E, Marinescu V, Maturi N, Tirfing M, Blokzijl A, Jin C, Chen L, Essand M, Swartling F, Nelander S, Jiang Y, Uhrbom L

5:56pm A CD133-Akt-Wnt signaling axis provides CSIG-22 functional insight into the role of CD133 in glioblastoma brain tumor-initiating cells Manoranjan B, Venugopal C, Mahendram S, Subapanditha M, Savage N, Qazi M, Vora P, Moffat J, Doble B, Singh S



M A I N M E E T I N G P R O G R A MSunday, November 19, 2017



Circulating Biomarkers - Technology and ApplicationAgnieszka Bronisz (Chair)

• EVs - biomarkers and effectors of the oncogene-driven cellular interactome in cancerJanusz Rak

• Glioblastoma transgenic mouse models for advance in biomarker studiesAlain Charest

• Immune evasion mediated by PD-L1 on glioblastoma-derived exosomesSean Lawler

• Heterogeneity of EVs cargo in the progression and therapeutic response in glioblastomaAgnieszka Bronisz

Clonal Evolution of GlioblastomaJoseph Costello (Chair)

• Clonal evolution and prediction of pharmacologic vulnerabilities of human gliomaAntonio Iavarone

• Deciphering single-cell programs in adult and pediatric gliomasMario Suva

• Deconstructing clonal composition in glioma through multiomic analysis of serial sectionsMichael Oldham

• Integrated model of clonal evolutionJoseph Costello

Viral Therapy: Advances from Bench to BedsideJames Markert (Chair)

• Determining the optimal dose for phase II/III studies of OV: The lesson of poliovirusAnnick Desjardins

• Combination of oncolytic adenoviruses and positive regulators of the immune synapsisJuan Fueyo

• Toca-511 trials and implications of survival-related mRNA expression profiles in OV trials for gliomaNoriyuki Kasahara

• Oncolytic HSV for glioma-potential for childhood cancers and use of immunogene therapyJames Markert

Discovery, Characterization and Functionalizing Novel Glioma GenesMelissa Bondy (Chair)

• Overview of glioma epidemiologic studiesMelissa Bondy

• Germline mutations in glioma families identified through whole genome sequencingMatthew Bainbridge

• Identification of novel SNPS identified through GWAS analysisMargaret Wrensch

• Developing functional pipelines to screen driver genes in mouse models of gliomaBenjamin Deneen

Meningiomas: Molecular Advances Toward Developing Targeted TherapiesGelareh Zadeh (Chair)

• Molecular testing in meningioma: beyond WHO gradeKenneth Aldape

• Lessons learned from genomic landscape of atypical meningiomasIan Dunn

• RNA pathway analysis directing therapeutic strategies in meningiomasGelareh Zadeh

• Challenges and opportunities in clinical trials for meningiomasMichael Jenkinson

Developing Cancer Stem Cell Targeting StrategiesJustin Lathia (Chair)

• Attenuating cell-cell communication in CSCs via drug repurposing strategiesJustin Lathia

• Targeting neurotransmission to compromise self-renewalPeter Dirks

• Sexual dimorphism in CSC drug responsesJosh Rubin

• Using pluripotent stem cells to model CSCs and identify novel drug targetsViviane Tabar



CONCURRENT SESSION 7APediatrics - ClinicalModerators: Annie Huang, Soumen Khatua

8:30-8:35am A phase I dose escalation trial of the MEK1/2 PDCT-24 inhibitor MEK162 (binimetinib) in children with low-grade gliomas and other Ras-Raf pathway-activated tumors: initial report Robison N, Pauly J, Malvar J, Filbin M, Loret de Mola R, Dorris K, Bendel A, Bowers D, Bornhorst M, Gauvain K, Leary S, MacDonald T, Gardner S, Reddy A, Diaz P, Tan Y, Sinai C, Davidson, MD T, Ullrich N, Margol A, Dhall G, Borchert M, Ligon K, Sposto R, Kieran M

8:35-8:50am Long-term impact of radiation dose and NCOG-15 volume on intellectual functioning (IQ) for children diagnosed with medulloblastoma: A report from the Children’s Oncology Group (COG) Embry L, Gioia A, Li Y, Han Y, Cullen P, Janss A, Michalski J, Billups C, Noll R, Hardy K

8:50-9:05am Neurocognitive outcome in children with s NCOG-12 ensorineural hearing loss following treatment for malignant embryonal brain tumors Moxon-Emre I, Dahl C, Ramaswamy V, Bartels U, Tabori U, Huang A, Cushing S, Papaioannou V, Laperriere N, Bouffet E, Mabbott D

9:05-9:20am Clinically integrated sequencing significantly PDCT-14 alters therapy in children and young adults with high-risk glial brain tumors Koschmann C, Wu Y, Kumar C, Lonigro R, Vats P, Kasaian K, Cieslik M, Cao X, Frank K, Prensner J, Zureick A, Everett J, Anderson B, Mullan B, Marini B, Camelo-Piragua S, Vennneti S, Mc Keever P, McFadden K, Lieberman A, Leonard M, Maher C, Garton H, Muraszko K, Robertson P, Robinson D, Chinnaiyan A, Mody R

9:20-9:30am Molecular diagnostics reveal 60% higher PDCT-05 survival for molecularly-verified versus histopathologically-diagnosed pediatric supratentorial central nervous system embryonal tumors and pineoblastomas; a report from the Children’s Oncology Group ACNS0332 trial Hwang E, Kool M, Burger P, Capper D, Chavez L, Brabetz S, Williams-Hughes C, Billups C, Heier L, Jaju A, Michalski J, Li Y, Zhou T, Leary S, Heideman N, von Deimling A, Jones D, Gajjar A, Packer R, Pfister S, Olson J

9:30-9:40am Temozolomide with irinotecan versus PDCT-09 temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma/CNS PNET of childhood: Report of a COG Randomized Phase II Screening Trial Levy A, Krailo M, Chi S, Williams-Hughes C, Bancroft M, Villaluna D, Fouladi M, Gajjar A

9:40-9:50am Safety and efficacy of intraventricular PDCT-04 131I-labeled monoclonal antibody 8H9 targeting the surface glycoprotein B7-H3 in patients with CNS/LM disease Kramer K, Kushner B, Modak S, Pandit-Taskar N, Tomlinson U, Donzelli M, Wolden S, Zanzonico P, Humm J, Haque S, Souweidane M, Greenfield J, Basu E, Roberts S, Carrasquillo J, Lewis J, Lyashchenko S, Larson S, Cheung N

9:50-9:55am Radio-immunotherapy using the IDO-PDCT-06 inhibitor indoximod in combination with re-irradiation for children with progressive brain tumors in the phase 1 setting: an updated report of safety and tolerability (NCT02502708) Johnson T, Aguilera D, Al-Basheer A, Cooksey R, Eaton B, Esiashvili N, Firat S, Fiveash J, Foreman N, Fridlyand D, Friedman G, Giller C, Grosshans D, Heger I, Kelly M, Kennedy E, Knipstein J, Kolhe R, Liu A, Martin W, Mourad W, Pacholczyk R, Parker R, Rojiani A, Sadek R, Thornton A, Vahanian N, MacDonald T, Munn D

9:55-10:00am Liquid biopsy for monitoring of tumor GENE-43 response in children with diffuse midline glioma Panditharatna E, Kambhampati M, Yadavilli S, Sandy J, Yang X, Kilburn L, Crawford J, Magge S, Packer R, Prados M, Mueller S, Nazarian J

10:00-10:05am The active regulatory landscape of PDTM-23 ependymal tumors Mack S, Pajtler K, Chavez L, Pfister S, Kool M, Taylor M, Rich J

10:05-10:10am Discussion

10:10-10:20am BREAK

PEDIATRIC CLINICAL RESEARCH AWARD

PEDIATRIC CLINICAL RESEARCH AWARD

CONCURRENT SESSION 7BMolecular Pathology - Adult and PediatricModerators: Craig Horbinski, Sean Lawler

8:30-8:35am Introduction Roel Verhaak

8:35-8:50am Global reduction in H3K27me3, similar to PDTM-49 H3K27M mutant gliomas, is a molecular surrogate for pediatric posterior fossa- group A ependymomas Vennneti S, Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, Yip S, Hukin J, Sun Y, Schipper M, Chavez L, Margol A, Pekmezci M, Chung C, Banda A, Bayliss J, Curry S, Santi M, Rodriguez F, Snuderl M, Karajannis M, Saratsis A, Horbinski C, Kool M, Pfister S, Taylor M, Hawkins C, Korshunov A, Judkins A

8:50-9:05am Large scale tumor mutational burden PDTM-21 analysis of pediatric tumors provides a diagnostic tool for germline predisposition and reveals novel candidates for immune checkpoint inhibition Campbell B, Angelini P, Light N, Bouffet E, Larouche V, Samuel D, Stearns D, Cole K, Opocher E, Sabel M, George B, Ziegler D, Laperriere N, Meyn S, Malkin D, Shlien A, Tabori U

9:05-9:20am Integration of multi-region (epi)genomics PATH-45 with multimodality advanced imaging highlights glioma intratumoral heterogeneity Verburg N, Johnson K, Barthel F, Taylor M, Costello J, de Witt Hamer P, Wesseling P, Verhaak R

9:20-9:30am The natural course of hypermutator PATH-37 gliomas Kamiya-Matsuoka C, Shaw K, Loghin M, Penas- Prado M, O’Brien B, Weathers S, Alfaro-Munoz K, Yung W, de Groot J

9:30-9:40am Automated histopathologic classification of PATH-46 brain tumors using artificial intelligence Xie Q, Han D, Faust K, Aldape K, Zadeh G, Volynskaya Z, Djuric U, Diamandis P

9:40-9:45am Characteristic molecular profile changes GENE-10 in primary and recurrent gliomas depending on their histopathology Mukasa A, Nomura M, Saito K, Aihara K, Nagae G, Nejo T, Tanaka S, Takayanagi S, Takahashi S, Omata M, Nakamura T, Narita Y, Muragaki Y, Nagane M, Ueki K, Nishikawa R, Aburatani H, Saito N

9:45-9:50am Molecular heterogeneity among pediatric PATH-32 posterior fossa ependymoma Pajtler K, Wen J, Sill M, Lin T, Hübner J, Ramaswamy V, Jones D, Witt H, Chavez L, Tatevossian R, Grundy R, Merchant T, Onar- Thomas A, Taylor M, Pfister S, Korshunov A, Kool M, Ellison D

9:50-9:55am Comprehensive genomic profiling comparing PATH-20 primary CNS lymphoma to systemic diffuse large B cell lymphoma reveals biomarkers indicating potential benefit from immune checkpoint inhibitors Severson E, Vergilio J, Gay L, Daniel S, Elvin J, Suh J, Covert M, Brown C, Miller V, Stephens P, Ross J, Ramkissoon S

9:55-10:00am Molecular subgroups of adult ependymal PATH-24 tumors: an analysis of the German Glioma Network Witt H, Gramatzki D, Hentschel B, Pajtler K, Schackert G, Capper D, Sahm F, von Deimling A, Westphal M, Herrlinger U, Pietsch T, Löffler M, Reifenberger G, Pfister S, Tonn J, Weller M

10:00-10:05am Deep convolutional neural networks provide NIMG-35 rapid diagnosis of fresh brain tumor specimens imaged with Stimulated Raman Histology Hollon T, Pandian B, Niknafs Y, Lewis S, Camelo- Piragua S, Orringer D


10:10-10:20am BREAK

CONCURRENT SESSION 7CImmunology-Preclinical and Clinical IModerators: Duane Mitchell, Hideho Okada

8:30-8:35am Introduction John Sampson

8:35-8:50am Therapeutic potential of chlorotoxin-IMMU-08 redirected CAR-T cells against heterogeneous glioblastomas Wang D, Wright S, Chang W, Starr R, Yang X, Aguilar B, Brito A, Sarkissian A, Badie B, Forman S, Barish M, Brown C

8:50-9:00am H3.3K27M mutation-derived novelIMMU-41 neoantigen – characterization of the HLA-A2- binding epitope and a specific T cell receptor for development of T cell-based immunotherapy Chheda Z, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Carrera D, Shrivastav S, Liu S, Downey K, Chuntova P, Watchmaker P, Mueller S, Pollack I, Rajalingam R, Montero Carcaboso A, Mann M, Sette A, Hou Y, Okada H

9:00-9:10am Glioblastoma-derived IL-6 induces IMMU-38 immunosuppressive peripheral myeloid cell PD-L1 expression and tumor progression Lamano J, Lamano J, Choy W, Veliceasa D, DiDomenico J, Oyon D, Quaggin-Smith J, Fakurnejad S, Ampie L, Li D, Kesavabhotla K, Kaur R, James C, Parsa A, Bloch O


PEDIATRIC BASIC SCIENCE RESEARCH AWARD

PEDIATRIC BASIC SCIENCE RESEARCH AWARD

9:10-9:15am Lin-CCR2+ hematopoietic stem cells IMMU-65 overcome resistance to PD-1 blockade Flores C, Wildes T, Drake J, Abraham R, Mitchell D

9:15-9:20am Controlled expression of IL-12 improves IMMU-34 survival in glioma by activating the immune response in mice and humans Barrett J, Cai H, Miao J, Khare P, Chan T, Cooper L, Lebel F

9:20-9:25am ONO-AE3-208 promotes anti-tumor immune IMMU-42 activity and survival in glioma models Kohanbash G, Kotani T, Chuntova P, Shoger K, Jahan N, Shrivastav S, Carrera D, Downey K, Castro B, Takeda K, Okada H

9:25-9:30am Strategy to enhance DC migration for IMMU-57 increased efficacy of dendritic cell vaccine immunotherapy Dastmalchi F, Karachi A, Azari H, Mitchell D, Rahman M

9:30-9:35am Remodeling immunity against IMMU-29 medulloblastoma via RNA loaded nanoparticles Sayour E, De Leon G, Grippin A, Flores C, Pham C, Mitchell D

9:35-9:40am A phase 1 study of PF-06840003, an oral ATIM-29 indole 2,3-dioxygenase 1 (IDO1) inhibitor in patients with malignant gliomas Reardon D, Desjardins A, Rixe O, Cloughesy T, Alekar S, Gamelin E, Williams J, Meissen J, Taylor C, Lassman A

9:40-9:45am Expression of PD-L2, in glioblastoma; IMMU-10 implications as a biomarker for immunotherapy Ricklefs F, Hayes J, Speranza M, Krenzlin H, Costello J, Freeman G, Westphal M, Lamszus K, Chiocca E, Lawler S

9:45-9:50am Optical barcoding reveals immunoediting IMMU-62 of the clonal architecture and modulation of gene expression signatures in a syngeneic glioma model Mohme M, Maire C, Riecken K, Alawi M, Dührsen L, Neumann K, Lange T, Failla A, Zapf S, Fehse B, Westphal M, Lamszus K

9:50-9:55am Temozolomide-resistant CAR-T enhances IMMU-01 glioblastoma clearance by concurrent chemotherapy and immunotherapy Sampath P, Sengupta S, Junghans R

9:55-10:00am Checkpoint molecule B7-H3 is highly IMMU-45 expressed on medulloblastoma and proves to be a promising candidate for CAR T cell immunotherapy Theruvath J, Heitzeneder S, Majzner R, Cui K, Nellan A, Graef C, Cheshier S, Mackall C, Mitra S

10:00-10:05am Controlled local expression of IL-12 as gene IMMU-33 therapy concomitant with systemic chemotherapy improves survival in glioma Barrett J, Cai H, Miao J, Khare P, Dalsing- Hernandez J, Gonzales P, Chan T, Cooper L, Lebel F


10:10-10:20am BREAK

CONCURRENT SESSION 8APediatrics - Basic ScienceModerators: Michael Taylor, Robert Wechsler-Reya

10:20-10:30am Yap1 is necessary for tumorigenesis PDTM-11 and cancer stem cellmaintenance in SHH- induced medulloblastomas Natarajan S, George J, Olson J, Camargo F, Yun K

10:30-10:40am Targeting an olig2-dependent pathway TMOD-30 to inhibit tumor growth in primary and recurrent medulloblastoma He X, Zhang L, Lu R

10:40-10:50am Context-specific tumor suppressive function STEM-21 of the canonical Wnt pathway in pediatric medulloblastoma highlights a therapeutic strategy for treatment-refractory subgroups Manoranjan B, Venugopal C, Kameda-Smith M, Bakhshinyan D, Subapanditha M, Doble B, Singh S

10:50-10:55am Characterization of the senescence-PDTM-47 associated secretory phenotype in pilocytic astrocytoma and its role in oncogene- induced senescence Hohloch J, Selt F, Hielscher T, Sahm F, Capper D, Usta D, Ecker J, Oehme I, van Tilburg CM, von Deimling A, Schuhmann MU, Korshunov A, Jones D, Brummer T, Pfister SM, Witt O, Milde T

10:55-11:00am Genetic susceptibility and evolution of PDTM-25 pediatric IDH-mutant infiltrating astrocytomas Bornhorst M, Goecks J, Boue D, Broniscer A, Hwang E, Koschmann C, Marks A, Mody R, Mueller S, Orr B, Packer R, Solomon D, Turner J, Vortmeyer A, Nazarian J, Ho C

11:00-11:10am Investigating pediatric GBM using in vivo PDTM-45 somatic mouse mosaics with locus-specific, stably-integrated transgenic elements Kim G, Dutra-Clarke M, Levy R, Park H, Sabet S, Molina J, Akhtar A, Bannykh S, Danielpour M, Breunig J

11:10-11:20am Pediatric low-grade gliomas with CRAF gene PDTM-40 fusions are therapeutically distinct from BRAF-fusions based on dimerization mediated by N-terminal fusion partner Jain P, Fierst T, Han H, Smith T, Storm P, Waanders A, Resnick A


11:20-11:30am TCR Vb clonal expansion predicts response IMMU-30 to adoptive immunotherapy against medulloblastoma Flores C, Wildes T, Pham C, Abraham R, Mooree G, Mitchell D

11:30-11:40am Analysis of paired BRAFV600E mutant PDTM-38 glioma patient samples identifies novel resistance mechanisms to targeted BRAF inhibition Mulcahy Levy J, Sanford B, Morin A, Green A, Flannery P, Jones K, Banerjee A, Solomon D, Nicolaides T

11:40-11:45am Targeted inhibition of EZH2 and BET PDTM-28 bromodomain proteins for the treatment of diffuse intrinsic pontine gliomas Piunti A, Morgan M, Bartom E, Louis N, He X, Zhang A, Horbinski C, Marshall S, Rendleman E, Takahashi Y, Misharin A, Abshiru N, Lulla R, Saratsis A, Kelleher N, James C, Shilatifard A, Hashizume R

11:45-11:50am Rare SOX9+ cells behind MYC-driven TMOD-31 medulloblastoma recurrence Bolin S, Savov V, Borgenvik A, Garancher A, Rosén G, Suryo Rahmanto A, Hutter S, Rusert J, Fotaki G, Hill R, Dubuc A, Remke M, Cancer M, Ramaswamy V, Clifford S, Sangfelt O, Schüller U, Taylor M, Wechsler-Reya R, Weishaupt H, Swartling F

11:50-11:55am CD271 (p75NTR) as a novel diagnostic PDTM-05 marker and therapeutic target for SHH medulloblastoma Liang L, Morrison L, Tatari N, Ramaswamy V, Del Bigio M, Taylor M, Hawkins C, Chan J, Werbowetski-Ogilvie T


CONCURRENT SESSION 8BStem CellsModerators: Anita Hjelmeland, Sheila Singh

10:20-10:30am Super-enhancer screen identifies lipid STEM-10 metabolism as a cancer stem cell dependency in glioblastoma Gimple R, Mack S, Rich J

10:30-10:40am Genes preserving stem cell state in Group 3 TMOD-03 MB BTICs contribute to therapy evasion and relapse Bakhshinyan D, Adile A, Venugopal C, Singh M, Qazi M, Manoranjan B, Kameda-Smith M, Singh S

10:40-10:50am Targeting the SCF Ubiquitin Ligase in STEM-16 Glioblastoma Pinkham K, Hashemiaghdam A, Badr C

10:50-11:00am Quaking (Qki) loss enhances GSC stemness STEM-25 and promotes gliomagenesis through regulating intracellular vesicle trafficking Shingu T, Hu J

11:00-11:10am CRISPR/Cas9-edited human neural stem cells TMOD-42 give rise to brain tumors resembling glioblastomas Koga T, Benitez J, Markmiller S, D’Antonio M, Parisian A, Saberi S, Turner K, Hessenauer M, Thorne A, Zanca C, Mischel P, Frazer K, Yeo G, Cavenee W, Furnari F

11:10-11:20am Genetic editing of neural stem cells for STEM-37 intranasal therapeutic delivery to malignant brain tumors Yu D, Kim J, Kanojia D, Han Y, Mathis J, Chen C, Aboody K, Lesniak M, Balyasnikova I

11:20-11:25am Identification of novel targets in STEM-13 glioblastoma stem cells through CRISPR-Cas9 screening Xie Q, Prager B, Rich J

11:25-11:30am The conserved tumor suppressor Lgl1 STEM-05 regulates adult oligodendrocyte progenitor cell division mode and prevents premalignant phenotypes Daynac M, Petritsch C

11:30-11:35am Sox2 activates the expression of onco-miR-STEM-38 486-5p Lopez-Bertoni H, Michelson N, Kotchetkov I, Li Y, Laterra J

11:35-11:40am A translational repression program is STEM-36 associated with the stem cell state in glioblastoma Lee C, Yeu Y, Guenther U, Hwang T, Jankowsky E, Rich J

11:40-11:45am Targeting glioblastoma stem cells by STEM-31 perturbing a novel gene regulatory cluster to reduce tumor recurrence Deng C, Sebastian M, Le S, Chen D, Thomas N, Tran D

11:45-11:50am Transcriptome analysis of glioma stem-like STEM-39 cells reveals SOX2 regulates miR-425-5p expression Acanda de la Rocha A, Lopez-Bertoni H, Martínez- Vélez N, Guruceaga E, González-Huarriz M, Laterra J, Alonso Roldán M

11:50-11:55am The role of symmetric cell division in post STEM-40 therapy glioma stem cell expansion Baisiwala S, Hall R, Park C, Ahmed A



CONCURRENT SESSION 8CImmunology - Preclinical and Clinical IIModerators: Peter Fecci, Gary Kohanbash

10:20-10:35am Allogeneic tumor lysate / autologous ATIM-13 dendritic cell vaccines in newly diagnosed glioblastoma: Results of clinical trial MC1272 Parney I, Gustafson M, Peterson T, Steinmetz S, Dietz A

10:35-10:45am Alliance A071101: A phase II randomized ATIM-14 trial comparing the efficacy of heat shock protein peptide complex-96 (HSPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma Bloch O, Shi Q, Anderson S, Knopp M, Raizer J, Clarke J, Waziri A, Colman H, Bruce J, Olson J, Schwerkoske J, Parsa A, Uhm J, Kumthekar P, Galanis E, Parney I

10:45-10:55am Phase 2 trial of SL-701, a novel immunotherapyATIM-10 comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and survivin, in adults with second-line recurrent GBM Reardon D, Nabors B, Kumthekar P, Badruddoja M, Fink K, Lieberman F, Hu J, Dunbar E, Walbert T, Schiff D, Sherman J, Tran D, Ashby L, Butowski N, Iwamoto F, Moertel C, Schulder M, Chen J, Bullington J, Shemesh S, Brooks C, Goswami T, Peereboom D

10:55-11:05am PD-L1 expression predicts survival in IMMU-13 newly diagnosed glioblastoma patients receiving vaccine immunotherapy but not standard therapy alone DiDomenico J, Veliceasa D, Choy W, Oyon D, Lamano J, Ampie L, Parsa A, Bloch O

11:05-11:10am Phase 2 study to evaluate the clinical efficacy ATIM-12 and safety of MEDI4736 (durvalumab [DUR]) in patients with bevacizumab (BEV)- refractory recurrent glioblastoma (GBM) Reardon D, Kaley T, Dietrich J, Clarke J, Dunn G, Lim M, Cloughesy T, Gan H, Park A, Schwarzenberger P, Ricciardi T, Macri M, Ryan A, Venhaus R

11:10-11:15am Immunomarkers in the DNX-2401 (Delta-24-ATIM-08 RGD) oncolytic virus phase I clinical trial Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez- Canales J, Wistuba I, Hess K, Alonso M, Tejada S, Diez Valle R, Ewald B, Tufaro F, Lang F

11:15-11:20am Adoptive immunotherapy using lymphokine-ATIM-22 activated αβ T-cells improves temozolomide- induced lymphopenia in patients with glioma Kanemura Y, Sumida M, Okita Y, Yoshioka E, Yamamoto A, Kanematsu D, Handa Y, Fukusumi H, Nozaki Y, Takada A, Nonaka M, Nakajima S, Mori K, Goto S, Kamigaki T, Shofuda T, Moriuchi S, Yamasaki M

11:20-11:25am Population pharmacokinetic (PPK) analysis ATIM-19 of nivolumab flat and weight-based dosing regimens and associations with safety in patients with recurrent glioblastoma (rGBM) treated in checkMate 143 Shen J, Hruska M, Zwirtes R, Potter V, Paliwal P, Roy A, Bello A, Suryawanshi S, Lim M

11:25-11:35am Characterizing the immune landscape of IMMU-20 PD-1/PD-L1 in brain tumor immune cell population using CyTOF mass cytometry Lee A, Davidson, MD T, Galvez M, Nathanson D, Wang A, Liau L, Prins R

11:35-11:45am Enhanced T cells tumor recognition using IMMU-25 dendritic cells pulsed with chimeric RNAs encoding full-length LAMP-1 fusion constructs Yang C, Dechkovskaia A, Drake J, Guimaraes F, Kubilis P, Huang J, Mitchell D

11:45-11:55am Selection of glioma T-cell therapy targets IMMU-52 based on the analysis of tumor immunopeptidome and expression profiles Carrera D, Hayes J, Mueller S, Shelton S, Weinschenk T, Song C, Fritsche J, Schoor O, Kuttruff- Coqui S, Hilf N, Kohanbash G, Watchmaker P, Oldham M, Costello J, Singh H, Okada H



12:00-12:30pm Highlights of SNO 2017 Manish Aghi, Frank Furnari, Vinay Puduvalli

12:30pm ADJOURN

Society for Neuro-OncologyPO Box 273296 Houston, TX 77277-3296Tel: 713-526-6900 E-Fax: 801-421-0269

www.soc-neuro-onc.org

Date post:	19-Sep-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

REGISTRATION INFORMATION - SNO · This year’s gala dinner, the social highlight of the meeting,...

Documents